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Kaposi’s sarcoma-associated herpesvirus (KSHV) is a member of the gammaherpesvirinae subfamily and displays two distinct life phases, latency and lytic replication.
Infection with KSHV mostly results in a latent state. A small population of infected cells
can spontaneously undergo lytic phase, which is marked by abundant viral gene
expression and production of infectious viral progeny. Lytic replication is important for
transmission of KSHV in the population and development of diseases. RTA (replication
and transcription activator) is a master regulator of KSHV lytic replication. Expression of
RTA alone is sufficient to disrupt KSHV latency and initiate the lytic replication cascade.
The objective of this research is to understand how RTA stimulates lytic replication.
RTA utilizes its DNA binding ability and /or cooperates with co-activators to upregulate vial lytic gene expression for lytic replication. In the present and previous studies,
we identified three distinct RTA responsive elements (RREs) in an early gene (ORF57)
promoter, and all of them are located in close proximity to each other in the ORF57
promoter. Current study demonstrated that two adjacent RREs and a co-activator (RBPJκ) binding site are required for optimal transactivation of the ORF57 promoter by RTA.

These results present the first evidence that RTA targets multiple DNA motifs in
responsive viral promoter to achieve full transactivation.
We demonstrated that RTA is able to enhance the autophagy pathway through
interference of the interaction between an autophagy-related protein Beclin 1 and an antiapoptotic protein Bcl-2 by inducing Bcl-2 phosphorylation. This post-translational
modification is a result of the induction of c-JUN N-terminal kinase (JNK) signaling
pathway by RTA. In addition, a defective autophagy pathway specifically reduces RTAmediated transactivation of lytic gene promoters. These results indicate that RTA
activates autophagy to stimulate lytic gene expression and initiate lytic reactivation.
In conclusion, multiple non-conserved RREs and a co-activator binding site are
required for RTA-mediated transactivation, indicating that a complex mechanism exists
by which RTA transactivates lytic cycle gene expression. Additionally, RTA-induced
autophagy may provide an optimal condition for RTA to mediate lytic gene expression
and KSHV lytic activation, demonstrating that KSHV adopts cellular machinery for its
viral DNA replication.
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CHAPTER 1
LITERATURE REVIEW
Introduction
Kaposi’s sarcoma associated herpesvirus (KSHV) is one of several known human
oncoviruses (Epstein-Barr virus, hepatitis B virus, hepatitis C virus, human papilloma
virus, human T-cell lymphotropic virus, Merkel cell polyomavirus, JC virus, BK virus,
and KSHV for example). Kaposi’s sarcoma (KS), primary effusion lymphoma, and
multicentric Castleman disease are known to be caused by KSHV (31, 39, 160). It is a
member of the gamma-herpesviridae family (128). Like all herpesviruses, KSHV
displays two distinct phases of infection, latency and lytic production phase. In most
tumor cells, the virus persists in a latent form and expresses genes which regulate
apoptosis, cell proliferation, and angiogenesis. Only small subpopulations of tumor cells
support lytic replication (17, 151, 203). Therefore, the latent phase of infection plays a
primary role in KSHV oncogenesis (14). However, the lytic program allows the virus to
spread throughout the host and sustain the population of latently infected cells. In
addition, clinical studies have shown that a block in the lytic but not latent KSHV
infection in AIDS patients by ganciclovir treatment results in a dramatic decline in the
incidence of new KS tumors (118). Currently, substantial evidence suggests that lytic
replication is a prerequisite for KSHV pathogenesis. Replication and transcription
activator (RTA), encoded by ORF50 of the KSHV genome, is necessary and sufficient
for the initiation of lytic replication cycle of KSHV (184). RTA tethers transactivation
function in regulation of numerous viral gene expressions and then facilitates viral lytic
replication (162). To date, a number of RTA-targeted genes have been identified, and
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various mechanisms by which RTA can function to regulate these targets result from the
positive and negative participation of various cellular and viral proteins. Therefore,
investigating how RTA creates a suitable environment for lytic cycle gene expression and
lytic viral replication will lead to a better understanding of KSHV pathogenesis. This
review will attempt to summarize the literature related to KSHV as well as the molecular
mechanism involved in the regulation of the KSHV life cycle.

Clinical diseases and transmission of Kaposi’s sarcoma-associated herpesvirus
(KSHV)
KSHV-associated diseases
Human herpesvirus 8 (HHV-8) is the first known human member of the genus
Rhadinovirus and was discovered by Yuan Chang and Patrick S. Moore in 1994 (39, 128).
Viral DNA was identified by representational difference analysis of Kaposi’s sarcoma
(KS) tissues of AIDS patients (39). Accordingly, the virus was also named Kaposi’s
sarcoma-associated herpesvirus (KSHV). It has been determined by PCR analysis that
KSHV is present in all forms of KS: classical, endemic, AIDS-associated and posttransplant KS (126). Classical KS is an indolent form and typically affects the skin of
elderly men in Eastern European and the Mediterranean (Sardinia, Sicily, Israel, etc) (99).
In contrast to classical KS, endemic form of KS predominantly occurs in young people
and is commonly found in African countries such as Uganda, Malawi, and Kenya.
Endemic KS can be indolent or aggressive based on the lesion spread areas. The
aggressive endemic KS is usually found in young children who have lesions spreading to
the lymph nodes (3). The most aggressive form of KS is found in AIDS patients in
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developing countries, especially Africa. This form of KS can be life-threatening when KS
lesions spread to internal organs (1). Post-transplant KS, the form of KS associated with
immune deficiency, occurs in organ-transplant recipients who receive long-term
immunosuppressive therapies to prevent reject allografts (3, 139).
In addition to KS, KSHV is also associated with two lymphoproliferative
disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease
(MCD) (31, 160). Nearly 50% of MCD patients without HIV infection have KSHV
infection. All of HIV-positive MCD patients are infected with KSHV. Additionally,
about 13% of MCD patients develop KS (58, 140). PEL is a B-cell lymphoma with low
incidence and develops as serious effusion without any solid tumor mass. KSHV has
been suggested to play an important role in PEL pathogenesis due to high seroprevalence
of KSHV in PEL. However, KSHV infection may not be sufficient for PEL development
and other cofactors may be required. Epstein Barr virus (EBV) infection occurs in most
PEL cases (86%) suggesting EBV is a potential cofactor for PEL development (32, 62).
Similarly, HIV (human immunodeficiency virus) has been suggested to be a cofactor of
KSHV for KS development due to the decline in the incidence and mortality of AIDSassociated KS after the usage of anti-retroviral therapy (HAART) (86, 94, 167). In fact, it
has been reported that HIV Tat (the trans-activating protein) enhances KSHV
transmission into endothelial cells and also cooperates with KSHV proteins in promoting
tumorigenesis (5).

KSHV transmission
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To date, many studies have identified different potential routes and risk factors of
KSHV transmission and they could vary depending on the geographic regions where
these studies were conducted. The seroprevalence of KSHV is low in the United States
and Northern Europe, intermediate in the Mediterranean, and high in sub-Saharan Africa
(59, 83, 93, 185). Vertical transmission of KSHV can be found but is rare (115).
Horizontal transmission from mother to child or from adult to adult is believed to occur
mainly through saliva contact (19, 124, 141). In addition, sexual transmission is a
candidate of KSHV transmission due to existence of KSHV DNA in semen and female
genital tract samples (137, 187). Indeed, sexual transmission can be observed in
homosexual men, especially with HIV co-infection, and may be the major mode of
transmission (59, 119). Heterosexual transmission is still being debated (9, 10, 93, 113,
114, 153). KSHV transmission through blood transfusion is rare and is suggested to be a
risk factor in Uganda and United States (11, 84). Interestingly, recent studies reveal that
environmental cofactors, such as biting insects, drinking water, and crude plants (herbs)
in traditional medicines, could result in the increase in the prevalence of KSHV in subSaharan Africa and the Mediterranean (8, 45, 46, 121, 186).

Characterization of KSHV
Based on phylogenetic analysis, KSHV belongs to the gamma herpesvirus
subfamily that is closely related to herpesvirus saimiri, rhesus monkey rhadinovirus,
bovine herpesvirus 4 (BHV-4) and murine gammaherpesvirus 68 (HV68); thus, it is the
only human member of the rhadinovirus (gamma-2 herpervirus) family (128, 147).
KSHV has a typical herpesvirus structure containing the lipid envelope on the surface of
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viral particle, the icosaherdal capsid (162 hexagonal capsomeres) encasing viral DNAcontaining-protein core, and the tegument which is a protein-filled region between the
envelope and capsid. KSHV possesses a linear double-stranded DNA genome of 170 kb.
This large DNA genome is GC-rich (85%) and variable sequences of terminal repeat (TR)
at both termini of the genome and a long unique region (LUR), that is about 138 kb in
length. The TR region is responsible for tethering of the KSHV genome to chromosomal
DNA and serves as the origin of latent plasmid replication (13, 127). LUR contains
coding information for more than 87 open reading frames (ORFs). The specific ORFs
which are not homologous to the genes in the herpesvirus saimiri genome are named with
the prefix K and numbered sequentially (147). Among the KSHV genes, the K1 is highly
variability and this variability is used to classify KSHV into five K1 subtypes (A, B, C,
D,E) (60, 81, 208). The first tissue culture models (BC1 and BC2) for characterization of
KSHV were established from body cavity-based lymphomas (AIDS-BCBL) that were
derived from human immunodeficiency virus-positive patients (33). Later on, other cell
lines (such as BCBL-1 and BC3) were established from other PEL samples, and they
provide a good cell culture system for studying virus-host interactions (7, 25, 27, 28, 57,
146, 171). Nevertheless, viruses prepared from PEL cell lines usually have low primaryinfection efficiencies even though they are infectious for different cell types, including
monocytes, fibroblasts, lymphocytes, and keratinocytes. Moreover, primary-infected cells
are unable to sustain long-term virus growth and also lose the virus after several passages
(30, 95, 129, 133, 144). The other useful system for studying virus is a recombinant
KSHV genome DNA, BAC36 (204). BAC36 has been engineered by cloning the fulllength viral genome into a bacterial artificial chromosome (BAC) and viruses can be
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recovered in human embryonic kidney 293 cells and human umbilical vein endothelial
(HUVEC) cells (67) (204). This has the potential to allow characterization of individual
viral genes.
KSHV is similar to other herpesviruses and displays two different phases in its
life cycle, latency and lytic replication. Accordingly, all viral genes are classified into
latent and lytic genes, and their expression patterns in latency and lytic phases have been
studied in cell lines derived from PEL, de novo infection of cultured cells, and biopsies
from KS, MCD, and PEL (171). According to the results of in situ hybridization of KS
biopsies, the majority of tumor cells in the lesions express viral latent transcripts, but a
subpopulation of tumor cells (1-3%) expresses lytic transcripts (161, 166). A number of
KSHV-expressed gene products are homologues of cellular proteins which function in
immunomodulatory, anti-apoptosis, and cell cycle regulation. Those viral proteins have
been suggested to deregulate the cellular signaling cascades during the viral infection and
thereby lead to tumorigenesis (131). In addition to expressing functional proteins, KSHV
also produces non-coding but functional RNAs. Polyadenylated and exclusively nuclear
(PAN) RNA has 1077 bp in size and is transcribed during the lytic cycle (164). Its
function is to block the assembly of an mRNA-protein complex (mRNP) and retain
intronless RNA in the nucleus (47). Recently, twelve pre-microRNAs have been
discovered in the KSHV genome. Ten of these pre-microRNAs are localized in the noncoding region between K12 and K13, and two are identified within the K12 gene (24, 136,
149). All KSHV microRNAs are expressed during latency but they remain detectable
throughout the lytic cycle (23, 130, 150).To date, the functions of viral microRNAs
(miRNAs) are not fully understood but they have been suggested to regulate the KSHV
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life cycle and viral pathogenesis. One of KSHV miRNAs, miR-K11, is an orthologue of
cellular miR-155 and its expression causes the down-regulation of a set of mRNAs,
including genes that regulate cell proliferation. Since cellular miR-155 is associated with
B-cell transformation, the function of KSHV miR-K11 may be related to B cell
lymphoproliferative disease (69). Additionally, gene expression profiling in cells stably
expressing KSHV-encoded miRNAs shows that 81 cellular genes are significantly
reduced. Among these genes, the protein level of THBS1 (thrombospondin 1) is
decreased dramatically in the presence of KSHV miRNAs (150). THBS1 is a strong
tumor suppressor and anti-angiogenic factor (169); thus, KSHV miRNAs may contribute
to pathogenesis by suppression of THBS1 expression. KSHV-encoded miRNAs also
regulate the KSHV life cycle. miR-K3 inhibits KSHV lytic cycle by targeting nuclear
factor I/B which can activate the KSHV immediate-early gene (ORF50) promoter (108).
miR-K9 limits RTA expression by targeting the sequence in the 3’untranslated region of
RTA mRNA to prevent inappropriate entry into the lytic cycle (16). Conversely, miR-K5
can induce viral reactivation by repressing BCLAF1 (Bcl-2-associated transcription
factor 1), an apoptosis-inducing factor (207). These results indicate that KSHV-encoded
miRNAs plays role in controlling the balance between latency and lytic replication.

KSHV life cycle
Latency
KSHV establishes a lifelong latent infection in most infected cells. During a latent
infection, the viral genome persists as a circular episome in the nucleus of the infected
cell. The latent replication is dependent on the host DNA replication machinery, requiring
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host cellular DNA polymerase and accessory factors, and initiates at ori-P (the origin of
latent plasmid replication) followed by bidirectional replication (85). In addition, only a
restricted number of viral genes (latent genes) are expressed during latency (145, 203).
Due to limited viral gene expression and the absence of viral replication, no functional or
infectious virions are produced during this period. This small subset of latent gene
products, which can be detected in all three KSHV-associated malignancies (KS, PEL,
MCD), includes a microRNA cluster and proteins, LANA (latent-associated nuclear
antigen) encoded by ORF73, vCyc (viral cyclin) encoded by ORF72, vFLIP [viral FLICE
(Fas-associated death domain like IL-1β-converting enzyme) inhibitory protein] encoded
by K13, and Kaposin encoded by K12 (116, 134). Additionally, viral interferon
regulatory factor-3 (vIRF3; also named LANA-2) encoded by K10.5 can be detected in
latently infected PEL and MCD cells but not in KS cells (134).
The latent gene products presumably function to suppress host immune response,
promote cell growth, possess cell survival and maintain latency. LANA is expressed
abundantly in almost all latently infected tumor cells (134, 135). The major function of
LANA is to maintain episomal viral DNA in the infected cells through tethering of the
circularized viral DNA to host chromosomal DNA (13, 48, 198). LANA is also a
transcriptional modulator which can be either an activator (91, 143, 168, 181) or a
repressor (105). The most interesting example is that LANA suppresses the expression of
RTA, which is essential for initiation of lytic replication (96, 97). In addition, LANA
physically interacts with p53 to protect infected cells from undergoing apoptosis (65). To
induce cell cycle progression, LANA inactivates pRb (Retinoblastoma) through
interacting with unphosphorylated pRb (142).
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LANA also limits the distribution of GSK-3β in the nucleus to allow accumulation of βcatenin to activate cell proliferation-related genes expression (66). Based on these
findings, LANA has been suggested as a major viral protein for establishment and
maintenance of latency and also promotes oncogenesis.
In addition to LANA, vFLIP is the other latent gene product that inhibits lytic
replication via suppression of the AP-1 pathway (197, 202). vFLIP, which has a similar
function as cellular FLIP in anti-apoptosis, blocks Fas-mediated apoptosis through
inhibiting the maturation of procaspase-8 to protect infected cells from death (15).
Besides being anti-apoptotic, many studies provide evidence about the transforming and
oncogenic protential of vFLIP, which induces NFκB survival signaling through the
association with the IκB kinase complex and the heat shock protein 90 (40, 61, 64, 106,
163). For cell cycle progression, vCyc, a homologue of human cyclin D2, can promote
phosphorylation of pRb to induce cell cycle progression from G1 to S phase. During viral
latency, 17 KSHV miRNAs derived from 12 pre-miRNAs are expressed (207). Some
repress immediate-early gene expression, thus promoting the maintenance of latency (16,
108, 130).

The regulation of KSHV reactivation from latency
KSHV primarily persists in infected cells with a lifelong latency, and only a low
percentage of infected cells undergo spontaneous lytic replication (151, 203).
Nevertheless, lytic replication plays an important role in the maintenance of the
population of latently infected cells because infectious viral progeny is only produced
during lytic phase. In addition, a number of viral proteins expressed during the lytic cycle
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are involved in modulating paracrine secretion of growth and angiogenic factors required
for tumor growth and development (183). Thus, virus reactivation from latency becomes
a critical step for KSHV pathogenesis. The KSHV RTA is a key protein responsible for
the switch from latency to lytic stage of infection. Induced expression of RTA is
sufficient for virus reactivation. The major function of RTA is to regulate the subsequent
transcriptional cascade during the lytic cycle, which is described in “RTA function in
transcription” section (54, 162). Besides transcriptional regulation of lytic genes
expression, RTA is required for lytic viral DNA replication because it assembles the
DNA replication complex at ori-lyt (179). To efficiently initiate lytic cycle, RTA also
circumvents the innate antiviral defenses within host cells. RTA counteracts IFN
(interferon)-mediated antiviral defenses by inhibiting IFN and β production. RTA
mediated ubiquitination and degradation of IRF7 in a proteasome-dependent fashion is
crucial for interfering with IFN production (200). To activate lytic DNA replication, the
structure of viral DNA genome is also critical. In latency, the viral genome is maintained
as condensed heterochromatin during latency in the cells but the vial genome relaxes its
compact chromatin structure to an euchromatin state, after induction of lytic cycle, which
enables lytic gene expression and DNA replication. Hence, KSHV lytic reactivation can
be triggered by sodium butyrate (an inhibitor of histone deacetylases), TPA (an inducer
of histone acetyltransferases), and 5-azacytidine (an inhibitor of DNA methyltransferase)
(41, 123, 175).
There are also a number of studies demonstrating that cellular signaling pathways
are involved in the regulation of KSHV reactivation. For example, inhibiting Akt activity
enhances TPA-induced lytic replication and RTA expression (138), suggesting Akt
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maintains latency. Multiple mitogen-activated protein kinase (MAPK) signaling pathways,
MEK/ERK, JNK and p38 pathways, are required for KSHV reactivation (44, 190, 199).
Hypoxia activates HIF (hypoxia-inducible factors), a transcriptional factor, to up-regualte
lytic gene expression (51, 79). A major downstream effector of the Notch signaling
pathway, RBP-Jκ, mediates RTA-stimulated transactivation of lytic gene promoters, and
constitutive activation of Notch1 is sufficient to reactivate KSHV from latency (98). The
role of NF-κB in the context of the KSHV life cycle is compex (52). NF-κB is mainly
activated by vFLIP during latency for cell survival and proliferation, and activated NFκB can suppress RTA-mediated gene expression by interfering with RBP-Jκ interactions
(87, 120). Conversely, viral lytic reactivation requires down-regulation of NF-κB (20)
while some lytic gene expression (such as vGPCR) stimulates NF-κB expression (26,
117). Thus, the regulation between lytic replication and latency involves a complex set of
viral and cellular proteins, and a number of cellular signaling pathways. There is a tight
interplay between latency and lytic replication so that the virus can be maintained mostly
in latency to enable cell transformation. The virus also needs to be reactivated
periodically to spread viral progeny to neighbor cells and sustain the population of
latently infected cells.

Lytic cycle
Unlike latent DNA replication, KSHV lytic DNA replication is dependent on its
own DNA polymerase and other viral factors to initiate replication at ori-lyt (the origin of
lytic replication), then proceed via a rolling circle mechanism; thereby, viral DNA is
amplified rapidly during lytic phase. Lytic genes can be categorized into immediate-early
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(IE), early, and late genes according to their sensitivity to cycloheximide and
phosphonoacetic acid (PAA) (166, 205). After primary infection or upon reactivation
from latency, the mRNAs of IE genes are transcribed earliest and the process is
independent of de novo protein synthesis due to its resistance to inhibitor of protein
synthesis, such as cycloheximide. Usually, IE gene products possess gene regulatory
functions and directly activate early gene expression, which is sensitive to cycloheximide
but resistant to the DNA polymerase inhibitor (PAA) (166). The expression of early
genes is followed by late gene expression. The products of early genes are involved in the
viral replication machinery and late genes encode proteins that comprise the virion . As a
result of the lytic cycle, cell death and release of infectious viral progeny occur. In
addition, KSHV productive infection correlates with the development of KS and MCD (2,
17, 151). A number of clinical studies have reported that treatment of KSHV infectedAIDS patients by a drug ganciclovir, which specifically blocks lytic replication of KSHV,
results in a dramatic decrease in the incidence of KS (118). The evidence indicates that
lytic cycle of KSHV plays an important role in KSHV pathogenesis. In fact, certain viral
proteins encoded by lytic genes have oncogenic properties. The four viral interferon
regulatory factors (vIRFs) identified in the KSHV genome induce transformation of
established fibroblasts through inactivating the p21 tumor suppression and the p53
pathway (132). KSHV vIL-6 (viral interleukin 6), a homolog of the human IL-6, also
possesses transforming ability to promote hematopoiesis, plasmacytosis, and
angiogenesis through the induction of high VEGF (vascular endothelial growth factor)
expression (4). Viral GPCR (G protein-coupled receptor) encoded by ORF74 is the most
studied lytic gene in cell transformation and has been implicated as an important
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oncogene for tumorigenesis, especially in KS (12, 72, 92, 125, 154, 193). Various
mitogenic and survival intracellular pathways are stimulated by vGPCR (154, 155). Thus,
expression of vGPCR is able to cause transformation of different cell types, including
fibroblasts and endothelial cells (6, 12, 125) and can also promote the development and
progression of KS-like lesions in multiple animal model systems (89, 125, 193).
Although these lytic gene products have oncogenic potential and interruption of lytic
cycle can suppress disease progression, it is still unclear how viral gene expressed during
productive infection play a role in cell immortalizaton when the infected-cells are
destined to die.

KSHV replication and transcription activator (RTA)
RTA protein is encoded in the genomes of all gamma herpesviruses, including
Epstein-Barr virus (EBV), rhesus rhadinovirus (RRV), herpesvrius saimiri (HVS), and
murine herpesvirus 68 (MHV-68). Only the RTA protein produced by gamma-2herpesviruses (KSVH, HVS, and MHV-68) acts as a major lytic-replication activator (68,
165, 189). For EBV (gamma-1-herpesvirus), regulation of lytic reactivation from latency
requires two proteins, Rta and ZEBRA (63, 122). KSHV RTA has been suggested as the
essential lytic switch protein for KSHV from studies that involved deletion and
overexpression of RTA (112, 165, 191). A mutant recombinant KSHV genome
containing RTA gene deletion is incapable of viral replication and unable to produce viral
progeny upon tetradecanoyl phorbol acetate (TPA) treatment (191). However, expression
of RTA alone in latently infected cells is sufficient to initiate lytic reactivation from
latency (71, 112, 165).

14
RTA protein expression
KSHV RTA is encoded by the IE gene ORF50. ORF50 transcript is induced
within 4 h of sodium butyrate treatment in latently infected PEL cells and is spliced from
a major 3.6-kb IE transcript which contains the ORF50, K8, and K8.1 reading frames
(111, 166, 205). The promoter of ORF50 is heavily methylated in latently infected PEL
cells and in biopsy samples obtained from latently infected patients (41), but RTA
expression can be induced by demethylation of its promoter upon TPA treatment (41).
ORF50 promoter is also responsive to hypoxia and may be activated by XBP-1 (x-box
binding protein 1) under hypoxic conditions (22, 49, 79, 188). RTA is a transcriptional
protein and can auto-regulate its expression through indirectly binding to its own
promoter (36, 56). Cellular transcription factors, including OCT-1 (octamer binding
protein 1), C/EBP- (the CCAAT/enhancer binding protein  ), HMGB1 (high-mobility
group B1), Sp1, and Sp3, were shown to mediate RTA auto-regulation (80, 109, 148, 175,
201). A recent study showed that RTA expression can also be repressed by KSHV
encoded miRNA, miRK9, which targets the sequence in the 3’untranslated region of the
mRNA encoding RTA (16).
RTA is a 691-amino-acid nuclear protein which is composed of a basic DNA
binding domain in the amino-terminus, an acidic transactivation domain in the carboxyterminus and two potential nuclear localization signals (21, 184). The RTA protein is
highly phosphorylated (111) and, the phosphorylation of RTA is mediated by the cellular
Ste20-like kinase hKFC and poly(ADP-ribose) polymerase (PARP-1) (77). In addition,
RTA has E3 ubiquitin ligase activity and could direct ubiquitination of itself to affect its
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stability (200). Moreover, amino acids (aa) 520 to 535 of RTA protein regulate its protein
stability and DNA binding efficiency (36).

RTA function in transcription
RTA activates the transcription of a number of viral lytic promoters, including its
own promoter (56, 71). For example, RTA transactivates viral promoters that encode
polyadenylated nuclear (PAN) RNA (156, 159), K12 (kaposin) (37), ORF57, K8 (KbZIP) (110), K1 (18), K9 (vIRF) (42), ORF21 (thymidine kinase) (201), K5 (78), K6
(vMIP-1) (38), ORF6 (single-stranded DNA binding protein), K14 (vOX-2), ORF74
(vGPCR) (90), ORF59 (107), ORF47 (gL)(35), glycoprotein B (gB) (50, 206), K2 (vIL6)
(55), ORF60 and ORF61(176). RTA also positively regulates the latency gene ORF73,
suggesting a feedback mechanism for the establishment of KSHV latency (97). Besides
viral genes, RTA also activates transcription of cellular genes, such as cellular interleukin
6 (IL-6) (53), STAT3 (76), CD21, CD23 (34) and HEY1 (192). The molecular
mechanism by which RTA activates those target genes has been extensively investigated
by electrophoretic mobility shift assay, transient transfection assays, and in vivo
chromatin immunoprecipitation assays coupled with KSHV whole genome tiling
microarray (ChIP on chip). In summary, RTA regulates downstream gene expression
through direct recognition and binding to the responsive elements in the promoter region
or by interaction with cellular proteins which then bind to the promoter region (38). A
number of RTA responsive elements (RREs) have been identified in various target
promoters but they do not seem to share a conserved common DNA binding site (37, 38,
43, 55, 110, 157, 170, 182). The RRE in PAN and K12 promoters contain homologous
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sequence which can be directly bound by RTA with high affinities (37, 159, 178). The
direct binding of RTA to the RRE is necessary and sufficient for activation of PAN and
K12 transcription (38). The first identified potential RRE is in the ORF57 and K8
promoters and it consists of palindromic and AT-rich motifs (103, 110). This palindromic
RRE is also present in the origin of lytic DNA replication (ori-Lyt) and binding to RTA is
essential for ori-Lyt-dependent DNA replication (178). We and others have discovered
that multiple RREs in K8 and ORF57 promoters, and they do not share the same
consensus sequence (152, 177, 182). In addition, transcriptional activation by RTA
requires the presence of a cellular protein RBP-Jκ (recombination signal binding protein
which is the target of the Notch signaling pathway (38, 180, 182). RBP-Jκ also
mediate RTA-driven transactivation of the ORF6, K6, K14, LANA, ORF59, ORF47
promoters, and the RTA itself (35, 38, 97, 100-102, 107, 180). In addition to RBP-Jκ, a
number of other cellular proteins interact with RTA and synergize with RTA to upregulate RTA-responsive promoters. These proteins include C/EBP (the
CCAAT/enhancer binding protein ), OCT-1 (octamer binding protein 1), c-Jun, CBP
(CREB- binding protein)/p300, HGMB1 (high-mobility group B1), and Sp1. RTA
physically interacts with C/EBPand cooperates with K8 to up-regulate K8 promoter
activity through binding to the C/EBP binding site (174). As shown in the K8 promoter,
C/EBP also binds to its specific binding sites on the PAN and ORF57 promoters, which
enhances their transcriptional activities (175). However, the binding of C/EBP and
transactivation of the K8 promoter mediated by RTA may exhibit cell type specific
transcriptional functions (29). Another cellular protein, OCT-1 interacts with RTA and
contributes to the transactivation of the K8 promoter (29). The c-JUN protein also binds
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to RTA and AP1 binding sites and this interaction stimulates RTA-mediated
transactivation of the K8 and ORF57 promoters (173). The CBP/p300 protein complex
binds to the amino-terminal basic domain and the carboxyl-terminal transactivation
domain of RTA and modulates the transcriptional activation function of RTA (74). The
interaction between RTA and CBP/p300 represses the transcriptional activity of p53 and
p53-induced apoptosis (75). The HGMB1 protein has the ability to bind and bend DNA.
HGMB1 promotes RTA binding to various target promoters, including ORF57, PAN,
vIL-6 and K12, and also enhances RTA transactivation of these promoters (158). Sp1
binding to its binding site is essential for RTA-mediated transactivation of the thymidine
kinase promoter (201). Moreover, RTA recruits chromatin remodeling complex
SWI/SNF and the RNA polymerase II mediator TRAP to the viral promoter by proteinprotein interaction, which ultimately stimualtes viral gene expression (73).
Conversely, a number of viral and cellular factors have been identified to suppress
RTA-mediated transcription of lytic genes. These factors include KSHV K-bZIP (K8),
KSHV LANA, HDAC (histone deacetylase), PARP1 [poly(ADP-ribose) polymerase 1],
Ste20-like kinase hKFC (human kinase from chicken), K-RBP (KSHV RTA binding
protein), HEY1, TLE2 (transducin-like enhancer of split 2), NF-κB and IRF7 (interferon
regulatory factor 7) (74, 77, 82, 87, 88, 96, 104, 172, 192, 195). The expression of the
early gene K8 is up-regulated by RTA. However, this gene product, K-bZIP, reduces
RTA-mediated transactivation of the ORF57 and K8 promoters, but not the PAN
promoter (88, 104). Thus, K-bZIP appears to have promoter-dependent effects on RTA.
The KSHV latent gene product LANA directly represses the transactivation of the ORF50
gene promoter and also negatively affects RTA-mediated auto-activation. This

18
suppression could be due to the binding of LANA to the ORF50 gene promoter or the
interaction between LANA and RTA (96). HDAC normally serves as a transcriptional
repressor because it deacetylates histones and certain transacriptional factors, or directly
inhibits the transactivator’s function through protein-protein interaction. Similarly,
HDAC down-regulates RTA transctiption activation by interacting with the RTA protein
(74). PARP1and Ste20-like kinase hKFC also interact with RTA to modify the RTA
protein by phosphorylation and then suppress its recruitment onto viral promoters (77).
The other RTA-interacting protein, TLE2, competes with RBP-Jκ to bind to RTA and
consequently inhibits RTA transactivation function (82). K-RBP interacts with the
cellular co-repressor TIF1β and also directly targets GC-rich motifs on viral promoters,
which ultimately suppresses RTA-mediated tansactivation (194, 195). The RTAinducible gene, Hey1, was identified using DNA chip technology. Its promoter can be
activated by RTA; however, the Hey1 protein has a negative feedback on RTA
transactivity (192). IRF7 (interferon regulatory factory 7) suppresses RTA-mediated
transactivation of the ORF57 gene promoter by competing with RTA for binding to RRE
in the ORF57 promoter (172). NF-κB strongly reduces RTA-mediated transactivation for
most RTA-responsive promoters. NF-κB interferes with the binding of RBP-Jκ to the
RTA-responsive promoters (87).

RTA is a ubiquitin ligase
Besides having transcriptional activity, RTA also has E3 ubiquitin ligase activity
which allows E2 ubiquitin-conjugating enzymes to transfer ubiquitin molecules to the
target protein. Once the protein is modified by polyubiquitination, it is a target for 26S
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proteasome degradation. The Cys-plus-His-rich region of RTA possesses ubiquitin ligase
activity and directly polyubiquitinates IRF7, Hey 1 and even itself, which increases
protein degradation of these respective proteins (70, 200). For polyubiquitination of KRBP, two regions of RTA, the C-terminus located at the end of transactivation domain
and Cys-plus-His-rich region at the N-terminus, are required for promoting K-RBP
degradation through the proteasomal pathway (196). In addition, LANA and K-bZIP also
undergo proteasome-dependent degradation in the presence of RTA (196). Interestingly,
all of these proteins, which display less stability in the presence of RTA, serve as RTA
repressors for inhibiting RTA-mediated transactivation (88, 96, 172, 192, 195). This
result suggested that RTA may counteract the inhibitory effect caused by these repressors
during RTA-mediated lytic replication.

Research aims
The objectives of this research are to understand the mechanism by which RTA
regulates transcription of lytic genes and investigate the potential cellular machinery
employed by RTA for reactivation of the virus from latency. The RTA responsive
element (RRE) in the RTA target gene promoters plays an important role in RTAmediated transactivation. Our previous results as well as other published studies have
identified various RREs with non-conserved sequences in response to RTA. Thus, more
than one binding site exists between RTA and its target gene promoters. More studies are
needed to further substantiate the relationship between RTA and target gene promoter in
order to understand how RTA mediate gene expression. In addition to stimulating gene
expression directly, our earlier studies demonstrated that RTA promoted protein
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degradation through the 26S proteasome pathway, and this function correlated with RTAmediated transactivaiton and KSHV reactivation. There is substantial evidence
demonstrating that RTA can employ cellular machinery to establish an adequate
environment for KSHV lytic replication. Recently, autophagy was found to play an
important role in cancer and viral pathogenesis. Besides proteasome degradation,
autophagy is the other major cellular degradation pathway. Therefore, RTA may also
utilize the autophagy pathway to regulate KSHV lytic replication. The overall objective
of this study is to understand the molecular mechanism by which RTA mediates lytic
viral replication. The specific aims are:

1) To investigate the RTA responsive elements in the ORF57 promoter that allow
RTA-mediated transactivation.

2) To investigate whether RTA utilizes autophagy to regulate the KSHV life cycle.

3) To investigate the molecular mechanisms by which RTA regulates autophagy for
KSHV lytic replication.
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Abstract
KSHV RTA is well established as a key transcriptional activator which regulates
KSHV life cycle from latency to lytic replication. It is expressed immediately after
infection and activates a number of viral genes to lead to viral replication. The RTA
responsive element (RRE) in the RTA target gene promoters is critical for RTA to
mediate the transactivation. There are a number of non-conserved RREs identified in
various RTA responsive promoters, and AT-rich sequences have been proposed to serve
as RTA targets but no consensus RREs have so far been identified. Two non-conserved
RTA responsive elements (RRE1 and RRE2) which contain AT-rich sequence have been
identified previously in the one of KSHV lytic gene promoters, ORF57, which can be
strongly activated by RTA. In this study, based on homology to the consensus sequence
of EBV RTA RRE we identified a third RTA responsive element (RRE3) in the ORF57
promoter. This RRE consists of GC-rich sequence which can bind RTA both in vitro and
in vivo and plays a role in RTA-mediated transactivation of the ORF57 promoter. The
presence of two of the three RREs in close proximity to each other is required for optimal
RTA-mediated transactivation of the ORF57 promoter even though the presence of only
one RRE is needed for RTA binding. Our results suggest that the ability of RTA to
mediate transcriptional activation is distinct from its ability to bind to its target elements.
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Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV8) was first identified from the Kaposi’s sarcoma tissue of an AIDS patient in 1994 and
subsequently shown to be associated with Kaposi’s sarcoma (KS) and other
malignancies, including primary effusion lymphoma (PEL) and multicentric Castleman’s
disease (MCD) (4, 5, 8). According to nucleotide sequence analysis, KSHV belongs to
the gammaherpesvirus family (rhadinoviruses), with family members that include
Epstein-Barr virus (EBV) and herpesvirus saimiri (HVS) (26). As in all herpesviruses,
KSHV goes through latent and lytic phases of infection, with latency predominantly
found in infected B cells (31). During latency, a small subset of viral genes is expressed
in order to evade the immune response and maintain the viral genome in the host cells.
These latent proteins were also found to affect the survival and proliferation of the
infected cells in vitro (14, 24, 25, 28, 32). Viral lytic replication can be reactivated in
vitro by treatment with chemical agents, such as sodium butyrate or tetradecanoyl
phorbol acetate (TPA) (23) and in vivo by the KSHV-encoded transcription factor RTA
(replication and transcription activator) (22). Upon reactivation from latency, lytic viral
proteins are induced and expressed. These proteins are encoded by differentially
expressed genes; the immediate-early (IE) genes are transcribed first, followed by the
expression of early genes, and then late genes are expressed after viral DNA replication
(34).
RTA is an important viral regulatory protein encoded by the immediate-early
gene, ORF50. A striking feature of RTA is its ability to trigger KSHV lytic reactivation
by itself in latently infected cells (15, 21, 22, 31, 33), and KSHV with the RTA gene
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deletion is incapable of lytic reactivation (41). Therefore, RTA has been implicated to be
an important switch to control the transition from KSHV latency to lytic replication. RTA
protein is 691 amino acids in size and is a potent transcriptional factor consisting of a
DNA binding domain at the amino-terminus, two putative nuclear localization signals,
and a transactivation domain at the carboxyl-terminus. To date, a number of viral lytic
genes, including ORF50 itself, that can be regulated by RTA have been identified (1, 6, 9,
11-13). RTA has been shown to transactivate its target promoters either by directly
binding to RTA responsive element (RRE) or indirectly by interacting with cellular
proteins, such as KSHV RTA binding protein (K-RBP) (37, 42), CCAAT/ enhancerbinding protein alpha (CEBP-α) (38, 39), octamer-binding protein 1(OCT-1) (27), and
recombination signal binding protein-Jκ (RBP-Jκ) (18). RTA protein with its DNA
binding domain recognizes the RREs in the target gene promoters, and an AT-rich or
A/T-trinucleotide motif was considered to be a feature of KSHV RRE that can be found
in ORF57 and K8 promoters (19, 20). However, there is a lack of a consensus RRE
sequence because substantial diversity can be observed in the RREs identified in the
promoters of various KSHV genes found to be responsive to RTA. They include PAN
(polyadenylated nuclear RNA) (30), K12 (kaposin) (6), K2 (viral interleukin-6) (11) and
K1 (1) genes.
Epstein Barr virus (EBV) Rta, a homolog of KSHV RTA, also functions as an
activator of viral lytic promoters. A consensus EBV Rta responsive element (EBV RRE)
GNCCN9GGNG, where N can be any nucleotide, has been identified (16). Recently, the
optimal EBV RRE sequence, GTCC(C/A)(T/C)(C/G)N(A/G)NC(A/G)(T/A)GGCG, was
reported to be present in five EBV lytic-cycle promoters (10). Interestingly, a CCN9GG-
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like sequence can also be found in the KSHV ORF57 promoter (Fig. 1A). ORF57 is one
of the KSHV lytic genes, which is highly responsive to RTA. It encodes a posttranscriptional activator involved in mRNA export and plays an important role in KSHV
lytic replication. Previously, we and others (13, 20) have mapped a 40-bp segment of the
ORF57 promoter encompassing nt 81904-81943 on the viral genome as the target site for
RTA binding and up-regulation of ORF57 transcription. Two RREs (ORF57-RRE1 and
ORF57-RRE2) have been identified in this 40-bp segment (Fig.1A). The ORF57-RRE1
was found to share some homology with the delayed early gene K8 promoter sequence
(20, 36). ORF57-RRE2 was found to bind not only RTA but also to interferon regulatory
factor 7 (IRF7), and competition between RTA and IRF7 affects the regulation of ORF57
promoter by RTA (35). Even though these two RREs are AT-rich as predicted for RRE,
there is no similarity between them. However, upon inspection of ORF57 promoter, a
CCN9GG-like sequence distinct from ORF57-RRE1 and 2 can also be found. Thus, we
termed this CCN9GG-like motif in the ORF57 promoter as ORF57-RRE3. In this study
we characterized this third RRE element in the ORF57 promoter and found that it plays
an important role in conferring responsiveness of the promoter to KSHV RTA.

Materials and methods
Plasmids
RTA expression plasmid (pCMVtagORF50) which encodes Flag-tagged fulllength RTA was described previously (36). The β-galactosidase expression plasmid
pCMVβ which was used for the normalization of transfection efficiency was purchased
from BD Clontech. All ORF57 reporter plasmids were cloned in the pGL3-Basic vector
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(Promega), and p57p1, p57B1, p57B1M1, and p57E, have been described previously (13,
36). Plasmid p57-3RRE, p57-3RRE1, p57B2 and p57-3RRE4 contain ORF57 upstream
regions spanning from nt -184 to -20, -163 to -20, 130 -68 to -184, and -151 to -20,
respectively (the putative transcription start site at nt 82081 is designated as +1). Plasmid
p57p1m2 contains the same ORF57 promoter region from -525 to -73 as p57p1 but has
mutations in ORF57-RRE2 (the T nucleotides in poistions -141, -143, and -149 were
replaced with C; -145 to -147, CTT were replaced with AGC). Plasmids p57-3RRE3 and
p57-3RRE2 contain the same ORF57 promoter region as p57-3RRE but p57-3RRE2 has
a substitution in the RBP-Jk binding site (nt -163 to -151) by the PstI restriction enzyme
sequence, and p57-3RRE3 has a deletion in the ORF57-RRE2 (nt -151 to -138). Plasmid
p57B2M contains the same ORF57 promoter region as p57B2 but has mutations in
ORF57-RRE1 same as p57B1M1 construct.
Electrophoretic mobility shift assay (EMSA)
The probes were obtained by labeling the double-stranded oligonucleotides (Fig.
2A and 4A) with [α-32P]dATP (Amersham) and DNA polymerase I Klenow fragment
(New England BioLabs). Labeled probes were incubated with purified His-tagged, fulllength RTA protein expressed in Sf9 cells by Ni-NTA (Promega) for 30 min in a binding
buffer [10mM Tris-HCl (pH7.5), 150mM KCl, 5.7mM MgCl2, 1mM EDTA, 0.1 ug of
poly(dI·dC), 5 ug of bovine serum albumin, 0.38mM dithiothreitol, 0.38mM
phenylmethylsulfonyl fluoride, 50mM β-mercaptoethanol, 5% glycerol]. For competition
assays, the purified Sf9-RTA protein was incubated with nonradioactive competitor DNA
for 30 min, and then the labeled probe was added and incubated further for 30 min. The
binding mixtures were loaded onto a 4.5% polyacrylamide gel in 1x TGE buffer [5mM
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Tris, 190mM glycine, 1mM EDTA (pH 8.3)]. After electrophoretic separation at 200V,
gels were transferred to Whatmann 3MM paper, dried, and subjected to autoradiography
with Kodak X-ray film.
Transient chromatin immunoprecipitation (ChIP)
ORF57 reporter plasmid and RTA expression plasmid were co-transfected into
293T cells or TRExBJAB-RTA cells, provided by Dr. Jae Jung, by using lipofectamine
2000 reagent (Invitrogen) or Amaxa Nucleofactor. Transfection efficiency for 293T cells
was about 90% and for TRExBJAB-RTA cells it was about 70%. At 24 hours posttransfection, TRExBJAB-RTA cells were added with doxycycline to induce RTA
expression. At 40-48 hours post-transfection, the cells were fixed by the addition of 37%
formaldehyde to a final concentration of 1% for 10 min. The crosslinking reaction was
stopped by adding glycine to a final concentration of 0.125M for 5 min. Cells were
washed twice with 1X cold-PBS (Phosphate Buffered Saline) and were resuspended in
cell lysis buffer [5mM PIPES (pH8.0), 85mM KCl, 0.5% NP40, 1mM PMSF
(Phenylmethylsulphonylfluoride), protease inhibitor cocktail (Pierce)] for 10 min at 4°C.
After centrifugation, the cell pellets were resuspended in nuclei lysis buffer (50mM TrisCl pH8.1, 10mM EDTA, 1% SDS) and incubated for 10 min at 4°C. The resulting
solution was diluted 10-fold with dilution buffer (16.7mM Tris-Cl pH8.1, 167mM NaCl,
1.2mM EDTA, 0.01% SDS, 1.1% TritonX-100, 1mM PMSF, protease inhibitor cocktail)
and sonicated. After centrifugation, the supernatant was precleared with mouse IgG
(Santa Cruz) and immobilized protein A (Pierce).
Immunoprecipitation was performed by incubation at 4°C with anti-Flag M2
antibody (Stratagene) or anti-His antibody (Clontech). Immune complexes were collected
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by a further incubation with immobilized protein A for 1-2 h at 4°C. The beads were
washed four times with IP buffer (25mM Tris, 150mM NaCl pH7.2) and resuspended in
immunoPure IgG elution buffer (Pierce). After centrifugation, the supernatant was
neutralized with 1M Tris pH7.2. RNase A and NaCl were added, followed by incubation
at 65°C overnight to reverse the cross-linked DNA-protein complex. Proteinase K
(Stratagene) was added, followed by incubation at 55°C for 1-2 h. DNA extraction was
carried out using the miniprep kit (Qiagen) and analyzed by PCR using specific primers
located in reporter vector. DNA was quantified by TaqMan real-time PCR using TQMN
PCR core reagents (Applied Biosystems). For calculation of relative DNA amount from
quantitative real-time PCR, the Ct (threshold cycles) value of antibody-precipitated
sample was normalized by the Ct value of the input, and the normalized Ct value of p573RRED3 was compared with the normalized Ct value of p57-3RRE. The means and
standard deviations of the results for each promoter were calculated from the results of
two reactions obtained from three different transfection experiments.
Cell culture, transfection, and luciferase assay
BJAB cells (KSHV negative cell line) were grown in RPMI 1640 medium (Gibco
BRL) supplemented with 10% FBS and 100 ug/ml penicillin-streptomycin (Mediatech) at
37°C with 5% CO2. Transfection of BJAB cells was carried out using Amaxa
Nucleofactor according to the manufacturers’ recommendations. The transfection
efficiency was normalized using the β-Gal expression plasmid, pCMVβ, as the internal
control. Luciferase activities were determined by the Luciferase Assay System
(Promega). The results were averaged from three independent experiments.
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Results
The CCN9GG-like consensus sequence can be identified in a number of KSHV
promoters
To examine whether KSHV RTA directly binds to the RRE3 sequence of ORF57
promoter, we performed electrophoretic mobility shift assay (EMSA) using purified, Histagged full length RTA protein expressed in recombinant baculovirus-infected Sf9 cells.
The 18-bp, double-stranded oligonucleotides of ORF57-RRE3 were labeled (Fig. 2A) and
incubated with binding buffer either alone or with increasing amounts of RTA.
Oligonucleotides ORF57-RRE3 demonstrated a dose-dependent binding to RTA (Fig.
2B, lanes 1 to 4). To demonstrate the specificity of RTA binding to the ORF57-RRE3,
excess amounts of unlabeled ORF57-RRE3 and AP1 binding sequence were used as the
specific and non-specific competitors in competition experiments respectively. The
interaction of RTA and ORF57-RRE3 is specific as it can be competed by homologous
unlabeled oligonucleotides but not by AP1 oligonucleotides (Fig. 2B, lanes 5 to 7).
To further confirm that RTA binds to CCN9GG-like motif, an 18-bp
oligonucleotide fragment of K2-RRE and MIP-RRE (Fig. 2A) was used for EMSA.
Similar to ORF57-RRE3, strong binding to RTA was observed, demonstrating that the
K2-RRE and MIP-RRE containing CCN9GG-like sequence are also as RTA targets, and
this specificity was confirmed by EMSA using competitors (Fig. 2C and D). Our results
indicate that CCN9GG is a potentially conserved motif of KSHV RRE in addition to ATrich sequences identified previously, and CCN9GG-like motif could be a third RRE
located in the ORF57 promoter.
ORF57-RRE3 is required for RTA binding to ORF57 promoter
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To further confirm that ORF57-RRE3 mediates RTA binding to the ORF57
promoter in vivo, transient chromatin immunoprecipitation (ChIP) was carried out in
293T and TRExBJAB-RTA cells. The reporter construct containing ORF57 promoter,
shown in Fig.3A, and the Flag-tagged, full-length RTA expression plasmid were
cotransfected into 293T cells. The presence of ORF57-promoter DNA fragments within
the immunoprecipitated complex was confirmed by PCR amplification. As shown in Fig
3A, upper panel, lane 1, a strong band was detected in the presence of RTA and p573RRE plasmid containing all three RREs in the ORF57 promoter. The negative controls
with transfection in the absence of antibody failed to recover any PCR products (Fig. 3A,
lane 2). In contrast to p57-3RRE, the transfection of p57-3RRED3, which lacks RRE3 in
the ORF57 promoter element appeared to be less efficient in binding to RTA and resulted
in a weaker amplified band (Fig. 3A, lower panel, lane 1). This was also confirmed by
real-time PCR to quantitate the amount of precipitated DNA from 293T and TRExBJABRTA cells, and RRE3-lacking DNA fragment resulted in about 65% reduction in binding
to RTA in 293T cells and 85% reduction in TRExBJAB-RTA cells (Fig. 3B). These
results suggest that ORF57-RRE3 is required for efficient binding of RTA to the ORF57
promoter.
RTA can bind to each of three ORF57-RREs independently
In an earlier study, we have demonstrated that RTA protein expressed in E. coli
can bind to the ORF57 promoter fragment 57R consisting of ORF57-RRE1 and RBP-Jκ
binding site (Fig. 4A) (35). Results in Fig. 2 demonstrate that RTA protein expressed in
baculovirus infected insect cells (Sf9) can bind to RRE3 in vitro. To further characterize
the binding of RTA to each of the three RRE elements, EMSA was carried out with DNA
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fragments containing each of these elements (Fig. 4A). Multiple high molecular weight
shifted bands were observed with the 57R labeled probe (Fig. 4B). Interestingly, we also
observed the interaction of RTA and RRE1 which lacks the RBP-Jκ consensus sequence,
and only a single complex was detected (Fig. 4C). Similarly, only one band was detected
with ORF57-RRE2 probe (Fig. 4D). Fig. 2 and 4 suggest that Sf9-RTA can directly bind
to each of the three ORF57-RREs. The binding does not require the RBP-Jκ consensus
sequence, but the presence of RBP-Jκ binding site may contribute to the formation of
multiple complexes.
The binding of RTA to ORF57-RRE3 is weaker than ORF57-RRE1 and 2
To further investigate the differential ability of each ORF57-RRE to bind to RTA,
cross-competition assays were carried out. As expected, the binding of RTA to each
ORF57-RRE probe was competed efficiently by its homologous unlabeled
oligonucleotide (Fig. 5, lanes 2 to 5, 17 to 20, 32 to 35). ORF57-RRE1 binding to RTA
was reduced by about 50% with an excess of ORF57-RRE2 competitor (lanes 6 to 9), and
ORF57-RRE2 binding was also reduced by about 80% with an excess of ORF57-RRE1
competitor (lanes 21 to 24) based on quantification of the bands. The binding of RTA to
ORF57-RRE3 was competed efficiently by either the unlabeled ORF57-RRE1 or ORF57RRE2 (lanes 36 to 43). However, ORF57-RRE3 was unable to compete for binding to
RTA with either ORF57-RRE1 (lanes 10 to 13) or ORF57-RRE2 (lanes 25 to 28). Taken
together, these results show that RTA binding affinity of ORF57-RRE1 is comparable to
that of ORF57-RRE2, but the binding affinity of RTA to ORF57-RRE1 and ORF57RRE2 appears to be much stronger as compared to ORF57-RRE3.
Two RREs are required for RTA-mediated transactivation of ORF57 promoter
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To further verify that the binding of RTA to ORF57-RRE3 plays a role in the
transactivation of ORF57 promoter, transient transfection experiments were carried out
by co-transfection of the RTA expression plasmid with various reporter constructs of
ORF57 promoter as shown in Fig. 6A. The p57-3RRE reporter, which contains the 40-bp
segment, was induced effectively by RTA in BJAB cells (56-fold) (Fig. 6B).
Surprisingly, p57-3RRE1 reporter, lacking ORF57-RRE1, was still transactivated
effectively by RTA (63-fold), even though the AT-rich palindrome of ORF57-RRE1 has
been considered as a critical region for binding and transactivation by RTA (20). The
induction of p57B2 reporter with deletion of 48-bp segment in the C-terminal ORF57
promoter remained high (60-fold). The reporter p57B2M with mutation in ORF57-RRE1
and p57B1reporter with deleted ORF57-RRE3 still remained highly responsive to RTA
as compared to p57B2. However, removal of ORF57-RRE3 and mutation of ORF57RRE1 (p57B1M1) significantly reduced the promoter’s responsiveness to RTA. These
results suggest that either ORF57-RRE1 or ORF57-RRE3 is not sufficient for efficient
RTA transactivation but at least one of these two elements in combination with ORF57RRE2 is required. This was confirmed by p57E reporter containing the ORF57-RRE3
alone, which showed a dramatic reduction in transactivation (Fig. 6B).
To further confirm the role of ORF57-RRE2 in RTA-mediated transactivation, the
ORF57-RRE2-deleted reporter (p57-3RRE3) was used. The transactivation of p573RRE3 reporter by RTA was almost abolished (Fig. 6B). To confirm that the loss of
transactivation response is not due to the deletion which shortened the length of ORF57
promoter between ORF57-RRE1 and 3, we tested the p57p1m2 reporter which contains
six nucleotide substitutions in the ORF57-RRE2 but the total length of the promoter
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remained the same. As expected, RTA responsiveness of p57p1m2 was still significantly
reduced comparing with p57p1 which is a positive control (Fig. 6C). Our results suggest
that ORF57-RRE2 is essential for RTA-mediated transactivation.
RTA-mediated transactivation of ORF57 promoter requires RBP-Jκ binding site
and two RREs
RBP-Jκ has been demonstrated to be a critical cellular factor for RTA-mediated
transactivation of the ORF57 promoter by binding to the RBP-Jκ binding site. The two
promoter reporter constructs p57-3RRE1 and p57B1, both containing the RBP-Jκ binding
site, were strongly activated by RTA (Fig. 6B), suggesting that RBP-Jκ binding site in
addition to the RREs is important. To further define the role of RBP-Jκ binding site and
two RREs in mediating RTA transactivation, the reporter p57-3RRE4 with deletion of the
upstream region of ORF57-RRE2, including RBP-Jκ binding site and ORF57-RRE1, was
tested. As expected, this reporter lost its responsiveness to RTA even though both
ORF57-RRE2 and ORF57-RRE3 were intact. In addition, RTA-inducibility was low with
the p57-3RRE2 reporter which has a deletion in the RBP-Jκ binding site but with intact
ORF57-RRE1, RRE2, and RRE3 (Fig. 6B). This is expected as RBP-Jκ is well
established as a co-activator of RTA that recognizes the consensus sequence located
between ORF57-RRE1 and ORF57-RRE2 to regulate ORF57 transcription (3, 17).
Interestingly, mutations in RRE2, clone p57p1m2, and mutation/deletion in RRE1 and
RRE3, clone p57B1M1, affected the transcriptional induction of ORF57 promoter by
RTA (Figs. 6B and C). The responsiveness of these two promoter constructs to RTA was
reduced substantially. Taken together, our results show that RBP-Jκ plays an essential
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role in RTA-mediated ORF57 transactivation but the presence of two RREs
(RRE1/RRE2 or RRE2/RRE3) is necessary.

Discussion
The role of ORF57-RREs in the RTA-mediated transactivation of ORF57 promoter
In this study, we have identified a third RRE, ORF57-RRE3, in the ORF57
promoter. It has a high G/C content which distinguishes it from the other two previously
characterized RREs in the ORF57 promoter, and similar RREs with high G/C can be
found in the promoter elements of several other KSHV genes which are responsive to
KSHV RTA. The three ORF57-RREs are located in very close proximity to each other in
the ORF57 promoter, and each has a unique sequence. Among the three RREs analyzed,
RRE2 seems to be essential for RTA mediated transactivation. However, the presence of
RRE2 alone is insufficient, and it requires the presence of either RRE1 or RRE3 for it to
be fully responsive to RTA. It is possible that for the ORF57 promoter, RTA may require
more than one RRE for it to regulate its expression and whether this is required for other
RTA responsive promoters, needs to be determined. Our results also suggest that RRE1
and RRE3 may play a similar role, each can be replaced by the other in combination with
RRE2 to mediate RTA transactivation, and the presence of at least two RREs elements is
required for transactivation. We found that the deletion of ORF57-RRE1 alone did not
affect the ORF57 transactivation mediated by RTA (Fig. 6A), which is in contrast to an
earlier report demonstrating that ORF57-RRE1 was critical for RTA binding and
transactivation (20). However, Lukac et al. tested only an isolated RRE1/RBP-Jκ
element, thus making any direct comparison with our ORF57 reporter studies difficult.
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We also observed that the amount of RTA bound to the promoter element
containing RRE1 and RRE2 alone is less than the intact promoter with all three RREs in
Fig. 3, yet their levels of transactivation by RTA are similar. It is possible that the amount
of RTA bound to RRE1 and RRE2 without RRE3 is adequate to reach the threshold level
of RTA needed to be recruited to the promoter element for it to mediate full
transactivation. Alternatively, it is possible that two adjacent RREs are needed for the
RTA complex to bind optimally since RTA has recently been reported to multimerize in
vitro (2, 19). In fact we have observed RTA multimerization in EMSA (Fig. 4B) with
multiple high molecular weight shifted bands using DNA probe containing ORF57-RRE1
and RBP-Jκ binding sites. These complexes could be due to spontaneous multimerization
of RTA as described previously (2, 19), but whether such complexes exist in vivo and
participate in binding to the two RREs and in the transactivation of ORF57 promoter
need to be further investigated.
In spite of the similar roles played by ORF57-RRE1 and 3 in mediating
transactivation, the binding affinities of RTA to ORF57-RRE1 and 3 are distinct, raising
the possibility that the binding affinity of RTA to different RREs may not be directly
proportional to the levels of RTA-mediated transactivation. Transactivation function may
require the presence of additional factors other than RTA; these may include both viral
and cellular factors. One such factor is RBP-Jκ which was shown to be a critical
transcriptional factor interacting with RTA to bind to RBP-Jκ binding site between
ORF57-RRE1 and 2 to activate ORF57 transcription (3, 17). Our data indeed reveal that
RTA-mediated transcription of ORF57 promoter can proceed only in the presence of all
three elements, the RBP-Jκ binding site, the ORF57-RRE2 and either ORF57-RRE1 or 3.
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Taken together, ORF57-RRE1 and 3 may be playing a secondary but necessary role to
enable the RTA-RBP-Jκ complex to bind to the ORF57-RRE2 and RBP-Jκ binding sites
in the ORF57 promoter to mediate transactivation. We are further investigating the exact
roles of ORF57-RRE1 and 3 in RTA-mediated transactivation.
The conserved sequence for KSHV RTA binding
KSHV RTA responsive elements have been extensively studied in past several
years (7, 19, 43). They have been found to be diverse and lack a consensus sequence, but
the exact motif mediating RTA binding and transactivation is still ambiguous. In contrast,
for EBV, its RTA RRE sequence GNCCN9GGNG has been identified in several EBV
lytic-cycle promoters to be responsive to EBV Rta. Our finding that CCN9GG-like
sequence can also be used by KSHV RTA to mediate transactivation of ORF57 promoter
suggests that EBV and KSHV RREs may share sequence homology, and it is possible
that CCN9GG-like motif could also be found in other RTA responsive promoters. Indeed,
in the KSHV PAN promoter, the major sequence in the PAN-RRE identified previously
for RTA recognition and transactivation contains the ACCN9GG consensus sequence
(Fig. 1B) (30). In addition, it was reported that another RTA responsive promoter MIP
lost its responsiveness with a deletion in the region encompassing nt 27855 to 27876 on
the viral genome (7). We found that this region contains not only the RBP-Jκ binding site
but also the ACCN9GG sequence, and have confirmed that RTA can bind to the MIP
ACCN9GG motif alone using EMSA. In contrast, Chang et al. failed to observe an
interaction between RTA protein and a DNA probe from the MIP promoter; this is not
unexpected because of an absence of the ACCN9GG motif in the DNA probe which was
used in the EMSA. Interestingly, ACCN9GG motif can also be found in the K2-RRE
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previously identified (Fig. 1B). It is located in a 26-bp region spanning from nucleotides
18293 to 18314 on the viral genome (11), and we have now shown that RTA binds to the
K2 DNA containing ACCN9GG sequence within this 26-bp region. Taken together, these
results suggest that the KSHV ACCN9GG motif is an important RTA target.
Studies on the EBV Rta responsive promoters which contain the recognition
sequence GNCCN9GGNG have shown that the differences in their binding affinities and
responsiveness to RTA transcription activation could be attributed to the N9 sequence
variation in each promoter element (7). Similarly for KSHV, the five promoters
containing the consensus sequence CACC(A/G)NTNGGN(C/G)NGG(T/C) that we have
identified here displayed similar variations in the N sequences (Fig.1B), and this variation
may play a role in their differential responsiveness to RTA transactivation. Indeed, it was
found that PAN-RRE has a stronger binding affinity and transactivation by RTA when
compared to K12 and K2-RRE even though all these RREs contain the
CACC(A/G)NTNGGN(C/G)NGG(T/C) motif (29). It is possible that the PAN N9
sequence is optimal for RTA binding; it is also possible that cellular factors may also
play a role in the differential binding and responsiveness of these promoters to RTA. A
number of cellular proteins, such as K-RBP, RBP-Jκ, OCT1, AP1, SP1, and CEBP-α, are
known to regulate RTA-mediated transactivation (9, 18, 27, 38-40), and some of their
binding motifs are found to be present in the vicinity of the
CACC(A/G)NTNGGN(C/G)NGG(T/C) motif. Thus, the combination of RTA binding to
these motifs with the presence of cellular factors may confer optimal activation of the
promoter. Taken together, it is likely that the ability of RTA to mediate transactivation is
distinct from its ability to bind to RREs and its binding affinity to these elements. Its
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ability to uncouple these two functions may play a role in its ability to regulate lytic gene
expression at different stages of the KSHV life cycle.
In summary, we have identified a new RRE sequence containing G/C-rich content
in five KSHV lytic gene promoters based on sequence homology to the consensus EBV
RRE. Whether this consensus RRE sequence CACC(A/G)NTNGGN(C/G)NGG(T/C) is
present in other RTA target genes and whether there are optimal N sequences required
needs to be further determined. This is also the first report to demonstrate that KSHV
RTA-mediated transcription requires two RREs in close proximity to each other. A better
understanding of the role played by RTA and various RREs will be needed to elucidate
the mechanism of RTA-mediated transactivation and induction of KSHV lytic
replication.
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Figures and figure legends
Fig. 1
(A)

(B)
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Fig. 1. Sequence comparison among RTA responsive elements (RREs).
(A) The sequence of the three potential KSHV RREs (RRE1, RRE2 and RRE3) in the
ORF57 promoter is in bold, italicized, and underlined. The recombination signal binding
protein-Jκ (RBP-Jκ) binding site is highlighted with double lines. (B) The alignment of
potential KSHV RREs which have homology to the EBV RRE CCN9GG in the ORF57,
K2, PAN, MIP, and K12 promoters. The identical sequences are shown by open boxes.
The numbers represent the nucleotide positions of the KSHV genome according to
GenBank U75698. The sequence of EBV RRE is in bold and N can be any nucleotide.
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Fig. 2
(A)

(B)

(C)

(D)
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Fig. 2. The binding of RTA to CCN9GG core sequence in vitro.
(A) The alignment between ORF57-RRE3, K2-RRE, and MIP-RRE. Identical sequences
are shown by vertical lines. The synthetic oligonucleotide fragments, ORF57-RRE3, K2RRE and MIP-RRE, used for EMSA are capitalized and bolded. (B) EMSA was carried
out by using the full length His-tagged RTA expressed in Sf9 cells and 32P-labeled
dsDNA probes. RTA binds to ORF57-RRE3. Lanes 1 was a control with 32P-labeled
ORF57-RRE3 probe alone. Increasing amounts of RTA protein were incubated with
probes in lanes 2 to 4. A 50 and 100-fold excess of unlabeled specific or non-specific
(AP1) competitors were incubated in the presence of purified RTA protein in lanes 5 to 7.
The arrows indicate the specific RTA-DNA complexes. (C, D) RTA binds to K2-RRE
and MIP-RRE. EMSA of K2-RRE and MIP-RRE was performed as described for panel
b. The arrows indicate the RTA and DNA complex.
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Fig. 3
(A)

(B)
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Fig. 3. Binding of RTA to the ORF57 promoter RREs in vivo.
(A) Transient-ChIP assay was carried out in 293T cells transfected with reporter plasmid
(p57-3RRE or p57-3RRED3) and Flag-tagged full-length RTA expression plasmid
(RTA). RTA-DNA complex was specifically precipitated with or without anti-Flag
antibody. Precipitated DNA was recovered by PCR with specific primers located in the
backbone of the reporter vector. (B) Taqman real-time PCR was performed to quantify
the immunoprecipitated promoter DNA from transfected 293T and TRExBJAB-RTA
cells.
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Fig. 4
(A)

(B)

(C)
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Fig. 4. Binding of RTA to ORF57-RRE1 and RRE2 is independent of the RBP-Jk
binding site in vitro.
(A) The solid lines show four DNA fragments (57R, RRE1, RRE2, RRE3) which were
labeled with 32P and used as probes for EMSA. (B, C, D) EMSA was performed with
RTA and the three DNA fragments, (B) p57R, (C) RRE1, and (D) RRE2. Conditions
used for EMSA were as described in Fig. 2. The unlabeled probes were used as specific
competitors, and AP1 was used as a negative control. The arrows indicate the RTA and
DNA complex.
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Fig. 5
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Fig. 5. The binding affinity of RTA to ORF57-RRE1 and RRE2 is higher than to
ORF57-RRE3.
The cross-competition EMSA was used to determine the differential binding ability of
RTA to the three RREs. The purified RTA protein (500 ng) was incubated with 40 fmole
of labeled probes in the absence or presence of homologous or non-homologous cold
competitors. An increasing amount (5x, 25x, 50x, and 100x) of various non-homologous
cold competitors were added. Nonspecific competitor AP1 was used a negative control,
and its fold in excess relative to labeled probes is indicated. Lanes 1, 16, and 31 represent
probe alone.
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Fig. 6
(A)

(B)

(C)
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Fig. 6. Two RTA responsive elements and RBP-Jk binding site are required for
RTA-mediated transactivation.
(A) Schematic representation of the ORF57 promoter reporter constructs and various
deletion and site-directed mutagenesis clones used in transient transfection analysis. Solid
lines indicate different regions of the ORF57 promoter segment with different deletions
or mutagenized regions (gray boxes). The responsiveness of each reporter to RTA
transactivation is indicated. (B, C) BJAB cells were used to analyze the promoter activity
of different ORF57 reporter constructs. Total DNA amount used in each transfection was
normalized by adding pCMVTag2A vector. Transfection of BJAB cells was carried out
with 0.8 µg of promoter reporter and 1 µg of RTA expression plasmid. Luciferase
activity was measured at 48 hr post-transfection.
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Abstract
Autophagy is one of two major degradation systems in eukaryotic cells. The
degradation mechanism of autophagy is required to maintain the balance between the
biosynthetic and catabolic processes and also contributes toward defense against invading
pathogens. Recent studies suggest that a number of viruses can evade or subvert host cell
autophagic pathway to enhance their own replication. Here, we investigate the effect of
autophagy on the KSHV (Kaposi’s sarcoma-associated herpesvirus) life cycle. We found
that inhibition of autophagy reduces KSHV lytic reactivation from latency, and an
enhancement of autophagy can be detected during KSHV lytic replication. In addition,
RTA (replication and transcription activator), an essential viral protein for KSHV lytic
reactivation, is able to enhance the autophagic process leading to an increase in the
number of autophagic vacuoles, an increase in the level of the lipidated LC3 protein and
the formation of autolysosomes. Moreover, inhibition of autophagy affects RTAmediated lytic gene expression and viral DNA replication. These results suggest that
RTA increases autophagy activation to facilitate KSHV lytic replication. This is the first
report demonstrating that autophagy is involved in lytic reactivation of KSHV.
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Introduction
Autophagy is an intracellular catabolic mechanism and is principally responsible
for degradation of long-lived cellular proteins and damaged organelles. The degraded
products are primarily recycled to supply nutrients when cells are undergoing nutrient
deficiency. The hallmark of autophagy is the formation of double-membrane cytosolic
vacuoles called autophagosomes which sequester entire organelles and large protein
aggregates. Eventually, autophagosomes fuse with the lysosomes to generate singlemembrane vacuoles termed autolysosomes, where the contents are subsequently degraded
and/or recycled by lysosomal hydrolases (34). This intracellular degradation system is
tightly regulated by a family of genes, known as autophagy-related genes (Atg), which
were initially described in yeast (27, 62). In higher eukaryotes, a number of Atg genes
homologous to yeast Atg have been shown to be essential for autophagy formation in
various eukaryotic systems (34). In addition to the classical homeostatic function,
autophagy plays an important role in multiple biological processes including
differentiation, development, anti-aging and cell death, and aberrant autophagy is
implicated in a number of human diseases, such as cancer, neurodegeneration, and certain
muscular myopathies (22, 35, 49).
The function of autophagy in cellular defense is to remove invading pathogens
including viruses; however, some pathogens have developed strategies to adopt the host
autophagic machinery for their own survival and replication (26, 33). The single-stranded
DNA virus B19 parvovirus infection induces autophagy to prolong survival of the
infected cells (42). The infection of the positive-stranded RNA viruses, such as poliovirus,
coxsackievirus and dengue virus, induces double-membrane vesicles resembling
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autophagosomes to increase viral RNA replication (21, 32, 53, 61). The induction of
autophagosomes by poliovirus is also proposed to play a role in non-lytic mechanism for
poliovirus release (21, 25). Autophagy is also an important innate immunity mechanism
which some viruses can evade by subverting or hijacking the autophagy process. For
example, Herpes simplex virus type 1 (HSV-1) ICP34.5 targets the mammalian
autophagy protein Beclin 1 to block the host autophagy machinery in order to induce
neurovirulence (43). Also, ICP34.5 can block autophagy through interference with
phosphorylation of eIF2 (eukaryotic translation initiation factor 2 alpha) by PKR (54).
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1), which is required for the
proliferation of infected B cells, utilizes autophagic degradation to limit its accumulation
in EBV-infected B cells (30). Human immunodeficiency virus type I (HIV-1) envelope
glycoprotein-mediated killing of uninfected CD4 T cells was found to be dependent on
the autophagy machinery and may be involved in the pathogenesis of AIDS (14, 15).
Overall, these studies present a complex picture defining the role of autophagy in the
viral pathogenesis but this effect is both viral and host strain specific.
Kaposi’s sarcoma-associated herpesvirus (KSHV) belongs to the gammaherpesvirus family and is associated with Kaposi’s sarcoma and other malignancies, such
as primary effusion lymphoma (PEL) and Multicentric Castleman’s disease (MCD). As
in all herpesviruses, KSHV exhibits two phases in its replication cycle, latent and lytic
phases. During latency, KSHV is capable of evading the immune surveillance to persist
in host cells without viral production; however, infectious viral particles can be produced
and released after induction of lytic reactivation from latency as a result of stress or
chemical stimuli, such as phorbol esters or sodium butyrate (4, 5, 39, 40, 46). In addition
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to in vitro stimuli, an immediate early KSHV gene, ORF50, encodes the replication and
transcription activator (RTA) which has the ability to initiate the entire lytic reactivation
cascade (38). RTA is a typical transcriptional factor containing an N-terminal DNAbinding domain and a C-terminal activation domain. RTA can trigger KSHV lytic
reactivation via the transcriptional activation of a number of viral lytic promoters (2, 6, 8,
11-13). However, in order for the virus to regulate between lytic replication and latency,
the transactivation function of RTA can be suppressed by various viral and cellular
repressors to limit the extent of lytic replication to return to latency (3, 17, 18, 20, 29, 58,
63-65). To overcome this suppression to facilitate lytic reactivation, viral RTA has the
ability to promote degradation of the repressors by modulating the ubiquitin-proteasome
pathway (16, 66, 67). Since a cellular regulatory mechanism is adopted by KSHV to
switch between lytic cycle and latency and various viruses have adopted the autophagy
pathway to regulate their replication, it will be of interest to determine whether KSHV
replication also involves the autophagy pathway. In this study, we found that the
activation of autophagy is enhanced during KSHV lytic reactivation, and the viral lytic
replication inducer RTA is involved in this activation.

Materials and methods
Cells, viruses, plasmids and reagents
Human 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM,
Invitrogen, Carlsbad CA) supplemented with 10% fetal bovine serum (FBS, Hyclone,
Logan, UT), 100 µg/ml penicillin-streptomycin (Mediatech) at 37°C with 5% CO2. For
starvation experiments, the cells were washed with 1x phosphate buffered saline (PBS)
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three times and incubated in the 1x Earle’s balanced solution (Invitrogen) for 90 min.
BCBL-1 is a KSHV–positive primary effusion lymphoma cell line and BJAB is a KSHVnegative cell line derived from Burkitt’s lymphoma. TRExBCBL1-RTA and
TRExBJAB-RTA both carrying a tetracycline-inducible RTA gene were provided by Dr.
Jae Jung (University of Southern California, Los Angeles, CA) (41). These B cells were
grown in RPMI 1640 medium (Gibco BRL) supplemented with 10% FBS and 100 µg/ml
penicillin-streptomycin at 37°C with 5% CO2. Vero cells infected by rKSHV.219 virus
were provided by Dr. Jeffrey Vieira (University of Washington, Seattle, WA) (57). The
cells were grown in DMEM supplemented with 10% FBS, 100 µg/ml penicillinstreptomycin, and 6 µg/ml puromycin (Sigma) at 37°C with 5% CO2. Bac50, a
recombinant baculovirus expressing KSHV RTA was also provided by Dr. Jeffrey Vieira
for generation of rKSHV.219 virus as described earlier (57). To establish knockdown cell
line, Beclin1 (BECN 1) and scrambled negative control (N) shRNA plasmids were
purchased from Origene and transfected into TRExBCBL1-RTA cells using the
nucleofector system (Lonza), and the transfected cells were selected by puromycin.
RTA expression plasmid (pCMVtagORF50) which encodes Flag-tagged full-length RTA
has been described previously (59). mRTA contains truncated RTA (amino acid 1 to 527)
which was cloned in pCMVtag-2A vector. Plasmid pGFP-LC3 encoding GFP-tagged rat
LC3 gene was obtained from Dr. Mizushima (Tokyo Medical and Dental University,
Japan) (23).
Bafilomycin A1, 3-methyladenine (3-MA), sodium butyrate (NaB) and 12-Otetradecanoylphorbol-13-acetate (TPA) were purchased from Sigma.
Flow cytometric analysis and cell viability assay
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The rKSHV.219 infected Vero cells were infected with Bac50 virus for 4 h and
treated with sodium butyrate (Sigma) for 24 h and/or 3-methyladenine (Sigma) at the
indicated time points. The cells were harvested and analyzed with a FACS calibur flow
cytometry using the Cell Quest software (BD Biosciences). rKSHV.219 infected Vero
cells were treated with 3-MA for 24 and 40 h and their viability was measured by a
Beckman Coulter with trypan blue staining.
Western blot analysis
Cells were harvested and the cell pellets were resuspended in M-PER buffer
(Pierce) containing protease inhibitor cocktail (Pierce) at 4°C for 20 minutes, followed by
centrifugation at 10,000 rpm for 5 minutes at 4°C. Cell lysates were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to
polyvinylidene difluorid (PVDF) membrane (GE healthcare), followed by incubation
with specific antibodies as described previously (65). LC3 antibody was purchased from
Abcam Inc, and BECN1 antibody against human Beclin 1 was purchased from Santa
Cruz biotechnology. For protein loading control, anti-tubulin antibody and anti-GAPDH
antibody were purchased from Santa Cruz biotechnology. For detection of His- and Flagtagged proteins, the HRP-conjugated anti-6xHis antibody and mouse anti-Flag M2
monoclonal antibody were purchased from Clontech and Stratagene. Anti-K8a antibody
was purchased from Novous and anti-RTA antibody was provided by Dr. Luwen Zhang
(University of Nebraska-Lincoln). The band intensities were measured by using the NIH
image software, image J.
Confocal microscopy and Lysotracker-red and DAPI staining
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Quantitative GFP-LC3 autophagy assays were performed in 293T and
TRExBJAB-RTA cells transfected with GFP-LC3 expression plasmids. The 293T cells
were grown in 35 mm coverslip bottom dish (BD Biocoat) and cultured under the
conditions indicated. To express RTA proteins in cells, RTA expression plasmid
(pCMVtagORF50) was cotransfected into 293T cells along with GFP-LC3 expression
plasmids. To induce RTA expression in TRExBJAB-RTA cells, the cells were treated
with doxycycline after transfection of GFP-LC3. For TRExBJAB-RTA, cells were fixed
using 4% paraformaldehyde in PBS for 15 minutes at room temperature, then washed
with PBS twice and deposited onto a slide for confocal microscopy visualization. A series
of optical images were obtained with an Olympus FV500 confocal system on an inverted
microscope, using the 488 nm laser line (522 nm emission) for GFP detection.
The cell containing ≥ 3 GFP-LC3 dots was defined as autophagy positive cells. The
number of cells with GFP-LC3 punctate dots relative to all GFP-LC3 positive cells was
counted (a minimum of 200 GFP-LC3 positive cells were counted in total for each
experiment) and is presented as percentages.
For lysotracker-red staining, the cells were treated with 1 μM lysoTracker Red
DND-99 (Invitrogen) at 37°C for 30 min. Depending on the experiments, 293T cells were
starved in Earle’s balanced salts solution (EBSS; Gibco-BRL) for 90 minutes in the
presence of lysotracker red dye. Then cells were fixed in 3.7% formaldehyde, and nuclei
were stained with DAPI (Calbiochem) for 10 min. Three channel, optical images (DAPI,
GFP, and Lysotracker) were collected using sequential scanning mode (405, 488, and 543
nm excitation; 450, 522, and 595 nm emission, respectively) of the Olympus FV500
confocal system.
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Transmission electron microscopy
293T cells were transfected with pCMVtagORF50 or pCMVtag (control)
plasmids and harvested at 24 h post-transfection. Cell pellets were washed with 1xPBS
once and fixed with 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 7.4) for 1 h at
room temperature. Fixed cells were dehydrated through a graduated ethanol series, and
embedded in Epon 812 (Electron Microscopic Sciences, Fort Washington, PA). Thin
sections (60-80 nm) were stained with uranyl acetate and lead citrate and observed under
a transmission electron microscope (Hitachi H7500-I). A series of ultrastructural images
were collected with a bottom-mount digital camera for confirmational analysis of
autophagy.
Real-time reverse transcription (RT)-PCR
Total RNA was isolated using an RNA mini kit (Qiagen) using protocol
recommended by the supplier. RNA samples were digested with DNase (Invitrogen) to
remove residual DNA. Real-time RT-PCR was carried out using iScript one-step RTPCR kit with SYBR Green. The primers used for the mRNA quantitation were ORF57
[5’- GCATATTTGGTAGCGATGGG-3’ (forward) and 5’GGGATAGTTAGGACAAAGGC-3’(reverse)] and K8.1 [5’CGCTCCTAATCCTATGCCTT-3’ (forward) and 5’-CTGATAAACCTGTCCACTCC3’ (reverse)]. All reactions were performed in duplicate. For calculation of the relative
mRNA amount from quantitative real-time PCR, the Ct (threshold cycle) value of each
viral gene was normalized by the Ct value of GAPDH, and the normalized Ct values from
samples were compared with the control samples (untreated).
Viral DNA copy number
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The intracellular viral DNA was extracted from TRExBCBL1-RTA cells using
genomic DNA purification kit (Gentra). The viral DNA was quantified by real-time PCR
using iQ SYBR Green supermix (Bio-Rad). To generate a standard curve for cycle
thresholds versus genomic copy numbers, the pCMVtagORF50 plasmid was serially
diluted to known concentrations. Primers for amplification of ORF50 gene were 5’CAAACCCCATCCCAACAT-3’ and 5’- AGTAATCACGGCCCCTT-3’. The DNA
copy number was calculated using Bio-Rad iCycler software (version 3.1).

Results
An autophagy inhibitor suppresses KSHV lytic reactivation
To investigate whether autophagy affects KSHV lytic reactivation, a specific
autophagy inhibitor, 3-methyladenine (3-MA), was used to suppress the autophagic
pathway in rKSHV.219 latently infected Vero cells, and cells were examined by
microscopy and flow cytometry (48). Vero cells were latently infected by a recombinant
green fluorescent protein (GFP)-red fluorescent protein (RFP) double-labeled
rKSHV.219 virus which constitutively expresses GFP. Upon induction of lytic
reactivation, cells will express RFP under the control of the lytic PAN promoter (57). It
had been shown that the highest number of cells expressing lytic proteins can be induced
by treatment with sodium butyrate (NaB) and infection of RTA expressing baculovirus
Bac50 (57). Therefore, we followed this protocol for induction of KSHV lytic
reactivation in rKSHV.219 infected Vero cells. Figure 1A shows that the number of cells
harboring reactivated KSHV at 40h post-induction was higher than at 24h post-induction.
However, in the presence of the autophagy inhibitor 3-MA the number of KSHV-
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reactivated cells was reduced when compared with untreated control. There was a 60%
reduction of RFP expressing cells at 24h after 3-MA treatment, and a 33% reduction at
40h, as determined by flow cytometry (Fig. 1B). The cells expressing GFP were not
affected by 3-MA treatment due to the similar percentage of cells expressing GFP in the
absence and presence of 3-MA (89.2% and 90.2% respectively; data not shown). In
addition, the similar cell viabilities were observed in both 3-MA treated and untreated
cells, indicating that the reduction in viral reactivation was not due to the toxic effect of
3-MA (Fig. 1C). These results demonstrated that 3-MA reduces KSHV lytic reactivation,
this reduction is likely due to its effect on autophagy, and the effect is most prominent
during early phase of lytic reactivation.
The activation of autophagy is enhanced during KSHV lytic replication
The conversion of microtubule-associated protein 1 light chain 3 (LC3) is a
hallmark of autophagy and has been used to detect autophagy activation. In quiescent
cells, LC3 protein is expressed in the cytoplasm as a precursor protein known as LC3-I
(18-KDa). When autophagy is activated, LC3-I can be conjugated to
phosphatidylethanolamine (PE) by a ubiquitination-like reaction to generate a lipidated
species termed LC3-II (16-KDa) which is associated with inner and outer membranes of
autophagosomes (19, 24). Therefore, to examine the status of the autophagy activation
during KSHV lytic replication, LC3 proteins were examined by Western blot analysis in
KSHV-positive cells. We observed that more LC3-II molecules were accumulated in
BCBL-1 cells after 12-O-tetradecanoylphorbol-13-acetate (TPA) and NaB treatments. In
addition, a time course study analyzing the cells at different time points after chemical
stimulation showed that there was an increase in the amount of the endogenous
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autophagic protein Beclin 1, which is known to be responsible for initiation of the
autophagic pathway (Fig. 2A). Therefore, the increase in the expression levels of two
autophagic proteins as well as the presence of KSHV lytic gene product K8 after TPA
and NaB stimulation indicate that the activation of autophagy is enhanced during KSHV
lytic replication.
The KSHV immediate early gene product RTA is considered to be necessary and
sufficient for KSHV lytic reactivation (38). Therefore, to determine whether the
activation of autophagy is also increased during RTA-induced lytic replication, LC3
conversion was analyzed in RTA-inducible BCBL-1 cells, TRExBCBL1-RTA. In this
cell line, RTA is integrated into the genome of BCBL-1 cells and its expression is
regulated by doxycycline (41). We demonstrated that overexpression of RTA in
TRExBCBL1-RTA efficiently triggers lytic replication as shown by the enhancement of
the expression of an early gene product, K8. Simultaneously, accumulation of LC3-II was
observed upon overexpression of RTA in TRExBCBL1-RTA cells (Fig. 2B). These
results indicate that there is an enhancement of autophagic process during KSHV lytic
reactivation upon RTA overexpression or treatment by chemicals.
RTA is able to increase the autophagic process in 293T cells
To investigate whether RTA is able to induce the autophagic process, the
presence of autophagic vacuoles was monitored after co-transfection of RTA and GFPtagged LC3 expression plasmids in 293T cells. Since LC3-II is lipidated and associated
with inner and outer membrane of autophagic vacuoles, the green fluorescent signal from
GFP-LC3 can be shifted from a diffuse cytosolic/nuclear staining to a punctate pattern
outlining the autophagic vacuoles in the cells if autophagy is triggered. In cells
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transfected with the control GFP vector and starved in salt buffer, no obvious green
punctate dots were observed (Fig. 3A). In contrast, green punctate dots of GFP-LC3 were
very distinct and found to be distributed in the cytosol after starvation and/or transfection
of RTA expression plasmids. No such GFP punctation was seen in GFP-LC3 transfected
cells in nutrient-rich media. The percentage of GFP-LC3 positive cells containing green
punctate dots was then quantified and the results are shown in Fig. 3B. Very few cells
(2%) transfected with pCMVtag vector were found to contain GFP-LC3 dots, and as
expected nutrition deprivation of these cells showed an increase in cells containing GFPLC3 dots to about 14%. Consistent with previous reports, we also observed that
transfection of Beclin 1, which is one of autophagic proteins important for autophagic
nucleation (36), moderately increased the number of GFP-LC3 dot containing cells to
about 4.2%. The number of Beclin 1 transfected cells containing GFP-LC3 punctate dots
markedly increases to about 19% upon starvation. Interestingly, over-expression of RTA
in the cells by transient transfection of the RTA expression plasmid dramatically
increased the percentage of GFP-LC3 dot containing cells (19.9%), which was further
increased to about 35% upon starvation. The increased number of cells containing GFPLC3 punctate dots was found to be dependent on the presence of RTA in a dosedependent manner (Fig. 3C). In addition, ultrastructural analysis of transfected 293T cells
by electron microscopy revealed an increased prevalence of double membraneautophagic vacuoles in the cytoplasm of the RTA transfected cells (Fig. 4B) as compared
to the vector-transfected 293T cells (Fig. 4A). To demonstrate that RTA-mediated
induction of autophagy is not an overexpression phenotype, a carboxyl-terminal truncated
RTA plasmid (mRTA) was overexpressed in the 293T cells for GFP dot analysis. The
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expression level of mRTA was much higher than the wild type RTA (Fig. 3D left panel)
but was not sufficient to enhance autophagy as indicated by the number of cells
containing GFP dots (Fig. 3D right panel). To confirm that the increase in GFP-LC3 dots
is due to the induction of autophagy, 3-MA was added to determine whether the presence
of GFP-LC3 dots can be inhibited. Indeed, 3-MA was able to reduce GFP-LC3 dot
expression even with the highest concentration of RTA added. There was a reduction of
GFP-LC3 dot expressing cells from 25 to 10% (Fig. 3C). To further confirm the ability of
RTA to induce the activation of autophagy, LC3 conversion was analyzed by Western
blotting. As expected, LC3-II accumulation was increased either in the presence of RTA
or upon starvation (Fig. 5A). Less accumulation of LC3-II was observed with the
transfection of vector alone. Together, these results indicate that RTA is capable of
inducing autophagic vacuole formation without involvement of other viral proteins.
RTA is capable of inducing the formation of autolysosomes
It is well established that the fusion of autophagosomes with lysosomes to
generate autolysosomes is a critical step in the autophagy degradation process. Moreover,
autolysosomes contain various lysosomal enzymes which are able to digest sequestered
material, including LC3-II which is associated with the inner membrane of
autophagosomes. Thus, to further determine whether RTA has the ability to stimulate the
maturation of autophagic vacuoles into degradative organelles, LC3-II accumulation was
analyzed by Western blotting in the presence of an inhibitor to prevent LC3-II
degradation by lysosomal enzymes. To prevent degradation cells were treated with
bafilomycin A1, a specific inhibitor of vacuolar proton-ATPases. As expected, cells
transfected with control plasmid pCMVtag showed an increase in LC3-II due to the effect
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of bafilomycin to prevent LC3-II degradation. However, the increase in the control cells
is less than those transfected with RTA. This indicates that fusion between the
autophagosomes and lysosomes were enhanced in the presence of RTA (Fig. 5A). To
further confirm this result, we assessed the presence of autolysosomes in cells by using
GFP-LC3 and Lysotracker red staining, which stains for acidic organelles such as
lysosomes. Clearly, in the RTA expressing or starved cells, LC3 was found to be
colocalized with Lysotracker suggesting the formation of the autolysosomes (Fig. 5B).
Together, these results indicated that RTA is able to induce LC3 conversion and the
formation of autophagosomes and autolysosomes to mediate the induction of the
autophagy degradation pathway.
The enhancement of autophagy activation by RTA is cell-type independent
To further demonstrate whether RTA-induced autophagic activation can be
observed in lymphoma cells, the autophagic vacuole formation and LC3 molecular
conversion were estimated in RTA-inducible BJAB cell line, TRExBJAB-RTA. In this
cell line, the RTA gene is integrated into the chromosomal DNA under the control of a
tetracycline-inducible promoter. TRExBJAB-RTA and control TRExBJAB cells were
first transfected with the GFP-LC3 plasmid, and GFP-LC3 punctate dots were analyzed
at the indicated time points after doxycycline treatment. Before addition of doxycycline
(at 0 h), both cell lines have similar basal number of cells containing GFP-LC3 dots, and
doxycycline is unable to enhance the formation of GFP-LC3 punctate dots in the control
cells TRExBJAB without the integrated RTA gene. In contrast, the percentage of cells
containing GFP-LC3 punctate dots was increased upon induction of RTA expression in
the TRExBJAB-RTA cells (Fig. 6A). In addition, the levels of the processed LC3-II
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proteins were found to be enhanced upon RTA induction in the TRExBJAB-RTA cells
but remained constant in control TRExBJAB cells (Fig. 6B). Consistent with our results
obtained with 293T cells, the increase in the autophagy activation by RTA is likely to be
cell-type independent.
Inhibition of autophagy affects RTA-mediated lytic replication
Our findings suggest that the autophagic process can be enhanced by RTA
expression, and Inhibition of autophagy affects KSHV lytic reactivation. Therefore,
inhibition of autophagy may affect RTA-induced KSHV lytic gene expression. To test
this possibility, we measured the mRNA levels of early and late genes (ORF57 and K8.1)
in RTA-inducible BCBL-1 cells (TRExBCBL1-RTA) in the presence or absence of an
autophagy inhibitor (3-MA). In the reverse transcription (RT) quantitative-PCR analysis,
induction of RTA by doxycycline was able to elevate the expression of ORF57 and K8.1
mRNA, indicating that lytic replication is triggered. However, suppression of autophagy
by 3-MA treatment leads to a reduction in RTA-induced lytic gene mRNA expression of
ORF57 and K8.1 (62% and 72% reduction, respectively) (Fig. 7A). To specifically
inhibit autophagy, we employed gene knockdown approach using shRNA against Beclin
1 which is required for initiation of autophagy (36). After transfection of shRNA plasmid
in TRExBCBL-RTA cells and puromycin selection, the reduction of Beclin 1 mRNA and
protein was confirmed by RT quantitative-PCR and Western blotting (Fig. 7B). We found
that RTA-mediated mRNA expression of ORF57 and K8.1 were decreased by 53% and
42% reduction respectively in the Beclin1 knockdown cells (Fig. 7C). It is well known
that RTA triggers lytic gene expression to facilitate KSHV lytic replication. Thus, we
also measured viral DNA copy number in the TRExBCBL-RTA cells with and without 3-
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MA treatment. Figure 7D shows that inhibition of autophagy by 3-MA reduces RTAmediated viral DNA replication (29% inhibition). Together, these results indicate that
autophagy positively regulates RTA-mediated lytic replication.

Discussion
Autophagy has been implicated to be an anti-viral immune defense and a number
of viruses were found to develop various strategies to block autophagy to overcome the
antiviral function of autophagy (28). However, several viruses have been found to utilize
autophagy to enhance viral replication. In our present study, autophagy is enhanced
during KSHV lytic replication and positively regulates KSHV lytic replication. It has
been shown that Infections by RNA viruses, such as poliovirus, coxsackievirus, influenza
A virus, hepatitis C virus and dengue virus, can induce autophagy and this induction
increases viral RNA replication and viral yield (1, 21, 32, 61, 68). Since positive-stranded
RNA virus replications are associated with cytoplasmic membranes of infected cells (47),
autophagosomes-like structures may serve as the membrane scaffold for viral RNA
replication based on the localization of their viral proteins and viral RNA genome in the
autophagosomes (21, 45, 60). In contrast to most RNA viruses, KSHV DNA replication
occurs in the nucleus. Therefore, it is unlikely that the autophagic vacuoles in the
cytoplasm can serve as sites for KSHV replication. It has been demonstrated that KSHV
adopts various cellular machineries and recruits different cellular proteins to maintain
latency or to initiate lytic replication (10, 66); therefore, autophagy could be one of the
cellular mechanisms utilized by KSHV to establish an adequate environment for lytic
reactivation.
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To explore the possible mechanism and biological significance of the
enhancement of autophagic activation during KSHV lytic replication, we tested the
ability of a key viral protein RTA, which is responsible for the initiation of KSHV lytic
reactivation, in the induction of autophagy. We observed that RTA possesses the ability
to increase the autophagic activation and this regulation is independent of other KSHV
viral proteins. Since RTA is a typical transcriptional factor located in the nucleus, it is not
clear how RTA can affect this intracellular pathway which occurs in the cytoplasm. It is
known that RTA up-regulate a number of intracellular and viral gene expressions (9, 37,
52, 56, 63); thus, it is possible that RTA promotes autophagic gene expression to trigger
the autophagic pathway. A similar mechanism has been found for hepatitis B virus
(HBV), where the HBV X protein can up-regulate Beclin 1 mRNA and protein levels to
activate autophagy in hepatocytes (55). Therefore, the relationship between RTA and
autophagy-related protein expression needs to be further investigated.
In the classic autophagic pathway, portions of cytoplasm are sequestered to form the
double-membrane vacuoles, autophagosomes. Subsequently, autophagosomes fused with
lysosomes to become autolysosomes where the degradation process occurs. However,
there are two reports showing the blockage of autolysosomal maturation by Hepatitis C
virus and coxsackievirus B3 even though the induction of autophagosome-like structures
can be observed during their infections, suggesting that the degradation function of
autophagy is blocked by Hepatitis C virus and coxsackievirus B 3 (51, 61). From our
results, we found that over-expression of RTA can enhance both autophagosomes and
autolysosome formation. There was an enhancement of GFP-LC3 and lysosomal staining
in the presence of RTA, which is similar to those observed during starvation. In addition,
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the increase in LC3-II protein level can be observed in RTA-expressing cells treated with
bafilomycin A1, suggesting that RTA is able to induce the autophagy degradation process.
A number of cellular and viral proteins have been shown to interfere with RTA-mediated
transcription of lytic genes to maintain KSHV latency (3, 18, 20, 29, 58, 63-65); hence,
the induction of autophagy by RTA to degrade these repressor proteins may be a
mechanism to enable the virus to initiate lytic replication. Since RTA has been shown to
promote protein degradation through the proteasome degradation pathway (16, 66, 67), it
is possible that RTA also adopts the autophagy degradation machinery for clearance of
cellular or viral transcriptional repressors to lead to KSHV lytic replication. Therefore,
further studies need to be conducted to demonstrate this possibility.
Currently, very little information is available regarding the roles of autophagy on
herpesvirus infection. Autophagy can be an antiviral defense against HSV and HCMV
(human cytomegalovirus) infection (7, 43, 44) but autophagy could also be an advantage
for viral infection, as in the case of EBV which use autophagy to regulate viral LMP-1
expression level (30). In our study, we have shown that KSHV RTA may play a role to
induce autophagy to enhance lytic replication; nevertheless, two other KSHV proteins,
vFLIP (31) and vBcl2 (50), have been reported to possess anti-autophagic function. It is
possible that KSHV can either enhance or suppress autophagy during different phases of
infection and dependent upon the expression of the various viral and cellular proteins
involved. Thus, the roles of autophagy seem to differ among different viruses and the
regulation of autophagy may involve various viral proteins and cellular proteins as in the
case of KSHV. How these various KSHV proteins function to regulate autophagy in
infected cells during various phases of the viral replication cycle needs to be determined.
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In conclusion, our study shows that the activation of autophagy is enhanced during
KSHV lytic reactivation, induced either by chemical stimuli or by RTA. RTA is able to
activate the entire processes of autophagy. Inhibition of autophagy diminishes RTAmediated lytic gene expression and reduces KSHV lytic replication; indicating that
autophagy is involved in KSHV lytic replication.
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Figures and figure legends
Fig. 1
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Fig. 1
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Fig. 1. Defective autophagy reduces KSHV lytic reactivation.
(A) rKSHV.219 latently infected Vero cells were infected with Bac50 virus and treated
with sodium butyrate (NaB) and cells with lytic replication were detected by RFP
expression observed under a fluorescence microscope. Cells were also treated with or
without 3-methyladenine (3-MA) for 24 or 40 h. The GFP fluorescence and phase
contrast micrographs are showed in parallel. (B) The RFP signal expressed from cells as
described for panel A were measured by flow cytometry. The results shown are based on
the average from three separate experiments. Results are expressed as mean +/- S.D.
Asterisks indicate p <0.05 (student’s t test). (C)The autophagic inhibitor 3-MA is not
toxic to cells. A Beckman coulter with trypan blue staining was used to measure cell
viability.
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Fig. 2
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Fig. 2. Autophagy is enhanced during KSHV lytic reactivation.
(A) BCBL-1 cells were treated with 20 ng/ml TPA and 3 mM NaB for the indicated time.
(B) TRExBCBL1-RTA cells were treated with 1µg/ml doxycycline (Doxy) for the
indicated time to induce RTA expression. Western blot analysis was performed using the
specific antibodies as indicated. The numbers below the blots indicate the relative
amounts of LC3-II protein which were normalized by GAPDH protein.
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Fig. 3
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Fig. 3
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Fig. 3. Induction of autophagic vacuoles by overexpression of RTA.
(A) confocal microscopy of autophagic vacuoles. GFP or GFP-LC3 plasmid was
cotransfected with pCMVtag or pCMVtagORF50 (RTA) expression plasmid into 293T
cells. At 22 h after transfection, the cells were cultured either in regular medium (nutrient
rich) or buffered saline, 1x Earle’s balanced solution, (starvation) for another 90 min. The
phase contrast micrograph is shown in parallel. Scale bars=10 µm. (B) Quantitation of the
number of cells containing GFP-punctate dots in transfected 293T cells. GFP-LC3 was
co-transfected with pCMVtag, Beclin 1 or pCMVtagORF50 (RTA) into 293T cells, and
the cells were cultured in regular medium (nutrient rich) or buffered saline (starvation).
(C) Induction of autophagy by RTA in a dose-dependent manner. An increasing
concentration of RTA expression was co-transfected with GFP-LC3 into 293T cells. An
autophagic inhibitor 3-MA was added into the transfected cells for 3 h. The number of
cells containing green punctate dots was then quantified. (D) The increase in the
autophagy by RTA is not due to protein overexpression. GFP-LC3 was co-transfected
with pCMVtag, pCMVtagORF50 (RTA) or mutant RTA (mRTA) into 293T cells and the
cells were cultured in regular medium. The protein expression levels of RTA and mRTA
are detected by Western blotting with anti-flag antibody as shown in the left panel. The
number of cells containing green dots is shown in right panel. All of results are based on
the average from three independent repeats. Results are expressed as mean +/- S.D.
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Fig. 4
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Fig. 4. TEM ultrastructural confirmation of autophagic vacuoles.
293T cells were transfected with pCMVtag (A) as a control or with pCMVtagORF50
(RTA) (B) and were cultured under nutrient rich condition. Arrows indicate autopahgic
vacuoles. N indicates nucleus. Panel B1, B2 and B3 are magnified views of auotphagic
vacuole structures from the boxed regions shown in panel B. M represents mitochondria.
Scale bars=1 µm.
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Fig. 5
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Fig. 5. Induction of autolysosomes by RTA.
(A) Western blot analysis of LC3 in 293T cells transfected with pCMVtag or
pCMVtafORF50 (RTA) and treated with bafilomycin A1 (as indicated by B) or DMSO
(control) for 4 h or salt buffer (as indicated by S) for 90 min. The numbers indicate the
relative amounts of LC3-II protein which were normalized with the GAPDH protein. (B)
Confocal microscopy of autolysosomes. The plasmids transfected into 293T cells were as
indicated. For starvation, the transfected cells were starved for 90 min in salt buffer.
Lysosomes were stained by Lysotracker red dye (red), autophagosomes were stained by
GFP-LC3 (green), and autolysosomes were stained by Lysotracker red and GFP-LC3
showing yellow signal. The nuclei were stained with DAPI (blue). Scale bars=10 µm.
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Fig. 6
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Fig. 6. Enhancement of autophagy by RTA in B cells.
(A) Induction of autophagic vacuoles by RTA. After transfection with GFP-LC3
plasmids, TRExBJAB and TRExBJAB-RTA cells were treated with doxycycline for the
indicated time. The number of cells containing green punctate dots was then quantified.
The results are from the average of three independent experiments. Results are expressed
as mean +/- S.D. (B) LC3 was analyzed by Western blot analysis of TRExBJAB and
TRExBJAB-RTA cells treated with doxycycline for the indicated time. The numbers
shown below the blots indicate the relative amounts of LC3-II protein which were
normalized with the GAPDH protein.
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Fig. 7
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Fig. 7. Defective autophagy reduces RTA-mediated lytic replication.
(A) Inhibition of autophagy by 3-MA affects RTA-mediated lytic gene expression.
TRExBCBL1-RTA cells were treated with different combinations of doxycycline (Doxy)
and 3-MA. ORF57 and K8.1 mRNA were quantified by real-time PCR. (B) Quantitative
real-time PCR and Western blot analysis detected the mRNA and protein levels of Beclin
1 from negative (N) and Beclin 1 (BECN 1) knockdown BCBL1-RTA cells. (C)
Inhibition of autophagy by knockdown of Beclin 1 reduces RTA-mediated lytic gene
expression. ORF57 and K8.1 mRNA levels from negative (N) and Beclin 1 (BECN 1)
knockdown BCBL1-RTA cells with or without doxycycline (Doxy) treatment were
quantified by real-time PCR. (D) Inhibition of autophagy reduces viral DNA replication.
Cellular viral DNA copy number from TRExBCBL1-RTA cells with different
combinations of 3-MA and doxycyclin (Doxy) was quantified by real-time PCR. The
results are from the average of three independent experiments. Results are expressed as
mean +/- S.D.
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CHAPTER 4
THE MOLECULAR MECHANISM OF RTA-STIMULATED AUTOPHAGY

Abstract
KSHV (Kaposi’s sarcoma-associated herpesvirus) is the etiological agent of
Kaposi’s sarcoma, which is a common neoplasm found in human immunodeficiency
virus-infected individuals. KSHV lytic reactivation from latency is critical for KSHV
pathogenesis. A viral protein, RTA (replication and transcription activator), plays a major
role in regulation of KSHV reactivation. Previously, we have demonstrated that a cellular
catabolic process involving degradation of the cellular components, autophagy, is
involved in RTA-mediated lytic replication because RTA can stimulate autophagy. In this
study, we found that Bcl-2 phosphorylation is increased in the presence of RTA and
inhibition of JNK activity decreases Bcl-2 phosphorylation. This reduction also affects
RTA-enhanced LC3 (microtubule-associated protein 1 light chain 3) conversion,
suggesting that the mechanism by which RTA stimulates autophagy is JNK-dependent
Bcl-2 phosphorylation. In addition, we determined that autophagy is not sufficient but
can cooperate with RTA to activate lytic replication. Inhibition of autophagy reduces
RTA-mediated transactivation of the lytic gene promoters. Collectively, these results
suggest that autophagy is activated and utilized by RTA to promote RTA-target gene
expression and facilitate virus lytic replication.
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Introduction
KSHV (Kaposi’s sarcoma associated herpesvirus) is a human oncogenic
gammaherpesvirus which is the etiology agent of Kaposi’s sarcoma (KS), primary
effusion lymphoma (PEL) and Multicentric Castleman’s disease (MCD) (2-4). It has been
implicated that the development of these malignancies involves not only latent KSHV
infection but intermittent periods of viral reactivation is also required (57). KSHV latency
involves the expression of a restricted number of viral proteins to maintain viral latency,
prevent cell death from apoptosis, inhibit immune recognition, and promote cell cycle
that can lead to cell transformation. During the lytic cycle, most viral proteins are
expressed and mainly function in viral replication and viral progeny production. In
addition to producing infectious virions, some lytic gene products can stimulate paracrine
signaling and cell transformation (57). With respect to KSHV-associated malignancies,
only a small fraction of infected tumor cells undergo spontaneous lytic replication.
However, clinical studies involving ganciclovir showed that interruption of lytic but not
latent replication can lead to KS regression, suggesting lytic viral replication is important
for tumor spread (32).
KSHV reactivation from latency is primarily controlled by an immediate early
gene product, the replication and transcription activator (RTA). Ectopic expression of
RTA is sufficient to induce viral lytic reactivation from latency (13, 30, 45). RTA acts as
a transcriptional activator to induce the expression of numerous virus lytic genes and
thereby facilitates the lytic replication program (5, 6, 8, 20, 43). To activate lytic gene
transcription, RTA either binds directly to the RTA responsive elements (RREs) in its
target gene promoters and/or requires the interaction with cellular transcriptional factors.
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In fact, a number of cellular proteins, such as recombination signal binding protein (RBPJk), CCAAT/enhancer-binding protein alpha (C/EBP), the high mobility (HMG) protein
HMGB1, octamer binding factor (Oct1), KSHV-RTA binding protein (K-RBP),
interferon regulatory factor 7 (IRF7), CREB-binding protein (CBP), poly(ADP-ribose)
polymerase 1 (PARP1), and Hey1, have been demonstrated to be involved in RTAmediated transcription (14-16, 50, 53, 56, 60, 62). However, among these transcriptional
factors, some repress RTA-mediated transcriptional activation by inhibiting the
recruitment of RTA onto the promoters of its target genes (14, 15, 50, 60, 62).
Conversely, RTA employs proteasome degradation as a mechanism to overcome the
suppression and these targets includ K-RBP, IRF7, and Hey1 (63, 64) (12). Therefore, to
achieve RTA-mediated lytic replication, the interplay between RTA and cellular factors
or other cellular pathways is critical. Previously, we have demonstrated another cellular
degradation process, autophagy, is involved in RTA-mediated lytic replication (56).
Autophagy is a self-digestion process which not only degrades proteins but also
digests unwanted organelles. Autophagy can be activated in response to various stimuli,
including nutrient deprivation, environmental stress (hypoxia, oxidative stress), microbial
infection, and organelle damage. Accordingly, this self-degradative process is involved in
cell survival, development, anti-aging, and innate or adaptive immunity (27). Conversely,
dysfunction of autophagy contributes to multiple human diseases including
neurodegenerative disorders, inflammatory bowel, and cancers (21, 28). The typical
hallmark in the autophagic process is the formation of autophagic vacuoles
(autophagosomes and autolysosomes). Autophagosomes are lipid-rich and protein-poor
vesicles with double membrane structure. The cytoplasmic constituents are invaginated
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and sequestered by the membrane when the isolated membrane is elongated to form an
autophagosome. When the outer membrane of the autophagosome fuses to the lysosome
to become an autolysosome, the internal content is delivered into the lumen of the
degradative compartment. Subsequently, the inner membrane of the autophagosome and
internal materials are degraded by lysosomal enzymes (10). Autophagy is a multistep
process which can be divided into three regulatory levels: The first level involves the
cellular signaling pathways upstream of the molecular machinery of autophagy; the
second level is molecular machinery which is related to the protein-protein interactions
and the activity of autophagy-related gene (Atg) products. This level is mainly
responsible for the formation of the autophagosomes. The third regulatory level is
involved in the maturation and fusion of the autophagosomes with the lysosomes (9).
A number of cellular signaling pathways in the first regulatory level have been
identified and can be categorized on the basis of mTOR involvement (17). mTOR
(mammalian target of rapamycin), a serine/threonine protein kinase, regulates cell
proliferation in response to nutrients, growth factors and cellular energy (ATP).
Conversely, mTOR can be inactivated by rapamycin leading to activation of autophagy,
suggesting that mTOR exerts an inhibitory effect on autophagy (61). It has been
demonstrated that amino acids- and insulin-induced signaling activate mTOR through
Rag proteins (Ras-related small GTPases) and class I PI3K (phosphatidylinositol 3kinase)-Akt pathway, respectively, to inhibit autophagy (1, 23). In contrast, low energy
(ATP) level, ROS (reactive oxygen species), ER stress, and hypoxia inhibit mTOR
activity through phosphorylation and activation of the TSC1/2 (tuberous sclerosis

140

complex1 and 2) complex by AMPK (5’ adenosin monophosphate-activated protein
kinase) that are able to induce autophagy (17, 19, 37).
In addition to the mTOR-dependent pathway, ER stress and hypoxia can also
stimulate autophagy through the mTOR-independent pathway which is related to Beclin
1. Beclin 1 is an ortholog of yeast Atg6 and plays an important role in the second
regulatory level of the autophagic process. Beclin 1 is part of a class III PI3K complex
and promotes the catalytic activity of class III PI3K for synthesis of a lipid,
phosphatidylinositol 3-phosphate, which is essential for the elongation of the
preautophagosomal membrane (phagophore) and recruitment of other autophagy proteins
to the phagophore (49). In normal conditions, this complex is interfered by an antiapoptotic protein Bcl-2 (B-cell leukemia/lymphoma 2) which directly interacts with
Beclin 1 (39). However, ER stress activates DAPK (death-associated protein kinase) to
phosphorylate Beclin 1 that causes the dissociation of Beclin 1 from Bcl-2 and induces
autophagy (65). Hypoxia induces the expression of BNIP3L (Bcl-2 adenovirus E1a
nineteen kDa interacting protein 3-like protein) to compete with Beclin 1 for binding to
Bcl-2, which in turn stimulates autophagy (48). Moreover, the dissociation of Bcl-2 from
Beclin 1 resulting in the induction of autophagy can also be triggered by nutrient
starvation or ceramide treatment. It was demonstrated that JNK 1 (c-Jun N-terminal
kinase 1) is activated in response to nutrient starvation or ceramides to disrupt the
interaction between Beclin 1 and Bcle-2 by phosphorylation of Bcl-2, thereby allowing
autophagy to proceed (38, 54).
We have previously shown that RTA is able to enhance the autophagy pathway
during KSHV lytic replication. In the current study, we further demonstrate that
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autophagy serves to enhance lytic replication initiated by RTA and plays an important
role in RTA-mediated transcription of lytic genes. In addition, we found that JNKdependent phosphorylation of Bcl-2 is involved in RTA-stimulated autophagy.

Materials and methods
Cells, plasmids and reagents
Human 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM,
Invitrogen) supplemented with 10% fetal bovine serum (FBS, Hyclone), 100 μg/ml
penicillin-streptomycin (Mediatech) at 37°C with 5% CO2. TRExBCBL1-RTA cell line
carrying a tetracycline-inducible RTA gene was provided by Dr. Jae Jung (University of
Southern California, Los Angeles, CA) (33). B cells were grown in RPMI 1640 medium
(Gibco BRL) supplemented with 10% FBS and 100 μg/ml penicillin-streptomycin at
37°C with 5% CO2. To establish knockdown 293T cell lines, Beclin1 (BECN 1), Atg5,
and scrambled negative control (Scramble) shRNA plasmids were purchased from
Origene and transfected into 293T cells using lipofectamine 2000 (invitrogen), and
transfected cells were selected by puromycin.
RTA expression plasmid (pCMVtagORF50) which encodes Flag-tagged fulllength RTA has been described previously (51). RTA Mutant plasmid pCMVtagRTA678,
pCMVtagRTA621, pCMVtagRTA579, and pCMVtagRTA527, which encode Flagtagged RTA amino acids 1 to 678, 1 to 621, 1 to 579, and 1 to 527, respectively, were
generated by inserting the PCR-generated DNA fragments into suitable sites of pCMVtag2A. Plasmid pGFP-LC3 encoding GFP-tagged rat LC3 gene was obtained from Dr.
Mizushima (Tokyo Medical and Dental University, Japan) (22). The β-galactosidase
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expression plasmid pCMVβ which was used for the normalization of transfection
efficiency was purchased from BD Clontech. Reporter plasmids pGL3-ORF57-3RRE
(containing ORF57 promoter), PanPluc (containing PAN promoter), and pHIVLTR-luc
(containing HIV long terminal repeat region) have been described previously (52, 55).
Plasmids pCDNA-Tat and pCMVtag-Beclin 1 express the full-length HIV Tat protein
and Flag-tagged full-length Beclin 1 protein, respectively.
Bafilomycin A1, doxycycline, and SP600125 were purchased from Sigma.
Rapamycin was purchased from Santa Cruz biotechnology.
Western blot analysis
Cells were harvested and the cell pellets were resuspended in M-PER buffer
(Thermo Scientific) containing protease inhibitor cocktail and Halt phosphatase inhibitors
(Thermo Scientific) at 4°C for 20 minutes, followed by centrifugation at 10,000 rpm for 5
minutes at 4°C. Cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and then transferred to nitrocellulose membrane (GE
Osmonics), followed by incubation with specific antibodies as described previously (62).
LC3 antibody was purchased from Abcam Inc. BECN1 antibody against human Beclin 1,
anti-Bcl-2 antibody, anti-tubulin antibody, and anti-GAPDH antibody were purchased
from Santa Cruz biotechnology. For detection of His- and Flag-tagged proteins, the HRPconjugated anti-6xHis antibody and mouse anti-Flag M2 monoclonal antibody were
purchased from Clontech and Stratagene, respectively. Anti-JNK, anti-phosphorylated
JNK, anti-phosphorylated Bcl-2, anti-mTOR, anti-phosphorylated mTOR, anti-p70S6K,
anti-phosphorylated p70S6K antibodies were purchased from Cell Signaling Technology.
The band intensities were measured by using the NIH image software, image J.
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Real-time reverse transcription (RT)-PCR
Real-time reverse transcription PCR was performed as described previously (56).
Total RNA was isolated using an RNA mini kit (Qiagen) using protocol recommended by
the supplier. RNA samples were digested with DNase (Invitrogen) to remove residual
DNA. Real-time RT-PCR was carried out using iScript one-step RT-PCR kit with SYBR
Green. The primers used for the mRNA quantitation of K8 were [5’GCCGAAGTATGTGATCAGTC- 3’ (forward) and 5’- ATTCGCATCAGCATGTCG3’ (reverse)]. The primers for ORF57 and K8.1 have been described previously (56). All
reactions were performed in duplicate. For calculation of the relative mRNA amount
from quantitative real-time PCR, the Ct (threshold cycle) value of each viral gene was
normalized by the Ct value of GAPDH, and the normalized Ct values from samples were
compared with the control samples (untreated).
Transfection and luciferase assay
Transfection of 293T cells was carried out by using Lipofectamine 2000 reagent
(Invitrogen) according to the manufacturer's recommendations. Luciferase assay was
performed as described previously (55). Luciferase activities were determined by the
Luciferase Assay System (Promega). The transfection efficiency was normalized using
the β-Gal expression plasmid, pCMVβ, as the internal control.
Quantitative GFP-LC3 autophagy assay
Quantitative GFP-LC3 autophagy assay was performed in 293T cells as described
(56). The 293T cells were grown in 35 mm coverslip bottom dish (BD Biocoat), and cells
were transfected with GFP-LC3 expression plasmid and plasmids expressing full-length
RTA or various RTA mutants. A series of optical images were obtained with an Olympus
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FV500 confocal system on an inverted microscope, using the 488 nm laser line (522 nm
emission) for GFP detection. The cell containing ≥ 3 GFP-LC3 dots was defined as
autophagy positive cells. The number of cells with GFP-LC3 punctate dots relative to all
GFP-LC3 positive cells was counted (a minimum of 200 GFP-LC3 positive cells were
counted in total for each experiment) and were presented as percentages.
Immunoprecipitation assay
Endogenous Beclin 1/Bcl-2 immunoprecipitation was performed in 293T cells by
lysing cells with lysis buffer (50mM Tris pH 7.9, 150 mM NaCl, 1mM EDTA, 1%
Triton-X100, protease inhibitor cocktail and Halt phosphatase inhibitors (Thermo
Scientific) at 4°C for 1 hour. Immunoprecipitation was performed with a monoclonal
anti-Bcl-2 antibody-conjugated to agarose (Santa Cruz biotechnology).

Results
Autophagy is not sufficient for initiation of KSHV lytic replication
We have demonstrated that autophagy is involved in RTA-mediated lytic
replication. To determine whether autophagy alone is sufficient to trigger KSHV lytic
replication, an autophagy inducer rapamycin was tested on RTA-inducible BCBL1 cells,
TRExBCBL1-RTA. In this cell line, RTA is integrated into the genome of KSHV
infected B cells, BCBL1, and its expression is regulated by doxycycline (33). To induce
autophagy machinery, the cells were treated with rapamycin for 48 hours and LC3
conversion was detected by Western blotting. LC3, microtubule-associated protein 1 light
chain 3, has been widely used as an indicator of autophagy activation. LC3 is
constitutively expressed in the cytoplasm as a precursor protein known as LC3-I (18
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KDa). When autophagy is activated, LC3-I is conjugated to phosphatidylethanolamine
(PE) becoming a lipidated molecule termed LC3-II (16 KDa). Hence, the change in the
molecular weight of LC3 protein indicates the presence of autophagy (18, 25). As shown
in figure 1A, an increase in LC3-II protein was observed in the presence of rapamycin,
indicating that rapamycin enhances the autophagic process. No significant changes in
mRNA levels of two early genes (ORF57 and K8) and one late gene (K8.1) were
observed in the cells treated with rapamycin alone, as measured by quantitative real-time
PCR. Nevertheless, RTA expression induced by doxycycline efficiently elevated mRNA
levels of those lytic genes, and addition of rapamycin could enhance RTA-mediated lytic
gene expression (Fig. 1B, C and D). These results suggested that rapamycin-induced
autophagy alone was unable to trigger KSHV lytic replication, but cooperated with RTA
to stimulate lytic gene expression.
Autophagy affects RTA transactivation function
In our previous study, we demonstrated that inhibiton of autophagy by knocking
down Beclin 1 RNA levels decreased RTA-mediated lytic genes expression (56). To
further substantiate that autophagy directly affected RTA-dependent transactivation of
the KSHV promoters, we established several gene knockdown 293T cell lines using
shRNA that targeted Atg5 or Beclin 1 (BECN1) to test whether autophagy altered the
ability of RTA to transactivate KSHV gene promoters. Two RTA targeted viral gene
promoters, ORF57 and PAN, as expected, were highly responsive to RTA in the negative
control cells transfected with a scrambled shRNA. However, luciferase activity was
decreased when the same cell line was transfected with shRNA directed against Atg5 or
Beclin 1 (Fig. 2A and B). In contrast, HIV Tat-mediated transactivation of the HIV LTR
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(long terminal repeat) promoter was not affected by any of the shRNAs tested (Fig. 2C).
This study suggested that the enhancement of transactivation by RTA was stimulated by
autophagy, and not the result of reduced general transcription activity. In addition, RTA
expression levels were comparable among negative control and gene knockdown cells,
indicating that the decrease in response of the two KSHV promoters to RTA in gene
knockdown cells was not due to changes in protein levels of RTA (Fig. 2D). Taken
together, autophagy was able to stimulate RTA-mediated transcription of gene promoters.
The transactivation domain of RTA is required for RTA-induced autophagy
To explore the potential mechanism by which RTA activates autophagy, we
determined whether the transactivation domain of the RTA protein was involved in the
induction of autophagy. A series of RTA mutant constructs with deletions in the Cterminus were expressed in 293T cells and their protein expression levels were similar
(Fig. 3A). These RTA transfected cells were further co-transfected with GFP-LC3
expression plasmid for visualization of autophagic vacuoles. In nutrient-rich condition,
LC3 protein is distributed in cytoplasm but is re-located to the inner and outer membrane
of autophagic vacuoles as a result of C-terminal conjugation to phosphatidylethanolamine
in response to stress, such as starvation; hence, the green dots can be observed if LC3 is
tagged with green fluorescence protein (GFP) (22). The results from GFP punctate dot
assay show that the RTA deletion mutant, RTA678 with a C-terminal deletion outside of
the transactivation domain induced autophagy with the same efficiency as wild type RTA
(Fig. 3B). However, the RTA527 mutant lacking 164 amino acids at the C-terminus of
RTA, which encompasses most of the transactivation domain, induced autophagy with
only about 32 % efficiency relative to wild type RTA. The deletion mutant RTA579,
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which lacks its C-terminus 112 amino acids, and RTA621, which lacks 70 amino acids,
were less effective than wild type RTA. RTA579 and RTA621 induced less autophagy
with 68% and 48% reduction respectively when compared to wild type RTA (Fig. 3B).
Our results suggest that the transactivation domain of RTA was important for induction
of autophagy.
To examine the transactivation ability of these RTA mutants, the activation of two
KSHV lytic gene promoters (ORF57 and PAN) were carried out using luciferase assay.
Like wild type RTA, mutant RTA678, possesses similar transactivation activity of both
target gene promoters. In contrast, dramatic reduction in luciferase activity was observed
with the two promoters when transfected with the RTA621, RTA579, or RTA527
mutants (Fig. 3C). Taken together, these results demonstrate that a partial deletion (from
a.a. 621 to 678) within the transactivation domain of RTA affects both RTA functions in
regulation of transcription of target promoters and its ability to induce autophagy. It is
possible that RTA may induce autophagy via up-regulating the expression of cellular
genes which are involved in autophagy.
RTA does not affect mTOR signaling
A well recognized pathway that regulates autophagy is the mammalian target of
rapamycin (mTOR) signaling, which negatively regulates autophagy. To determine
whether RTA induces autophagy through the inhibition of mTOR signaling, we examined
the kinase activity of mTOR in the presence and absence of RTA expression. The activity
of mTOR can be determined by measuring the level of phosphorylation of itself or a
substrate, ribosomal S6 protein kinase (S6K1, also known as p70S6K). We used an
autophagy inducer rapamycin as a positive control which blocks mTOR kinase activity to
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up-regulate autophagy, and the expression of Beclin 1 as a negative control which
activates autophagy independent of mTOR signaling (41). As expected, the addition of
rapamycin inhibited the phosphorylation of mTOR, thus increasing the frequency of
autophagy. Also as expected, expression of Beclin 1 has no effect on mTOR
phosphorylation but will induce autophagy independent of the mTOR pathway. For RTA,
we observed that the phosphorylation of mTOR and p70S6K was not affected by
overexpression of RTA, indicating that RTA may be similar to Beclin 1 and involves
mTOR-independent mechanism to activate autophagy (Fig. 4).
RTA disrupts the interaction between Beclin 1 and Bcl-2
Since RTA is incapable of inhibiting mTOR kinase activity for induction of
autophagy, it was possible that RTA may stimulate autophagy by directly regulating the
activity of the Atg machinery involved in autophagosome formation. Beclin 1 is one of
the Atg proteins responsible for initiating autophagosome formation and its effect on
autophagy is modulated by formation of complexes with various cellular proteins, such as
Bcl-2 which suppresses Beclin 1-mediated induction of autophagy (39). Thus, it is
possible that RTA may affect the association of Beclin 1 with this protein to mediate
autophagosome formation. By using immunoprecipitation assay, we found that the
interaction between Beclin 1 and Bcl-2 was reduced in cells transfected with RTA (Fig.
5). The expression levels of Beclin 1 and Bcl-2 were similar in empty vector and RTAtransfected cells; however, less Beclin 1 was associated with Bcl-2 in the RTAtransfected cells (Fig. 5). Since dissociation of the Beclin 1-Bcl-2 complex to stimulate
autophagy has been demonstrated under nutrient starvation and in response to BH3
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mimetic molecules (31, 54). We suggest that RTA may induce autophagy by interfering
with the interaction between Beclin 1 and Bcl-2.
RTA stimulates phosphorylation of Bcl-2
Post-translational modification of Bcl-2 by phosphorylation interferes with the
interaction between Beclin 1 and Bcl-2 during the induction of autophagy by starvation
and ceramides (38, 54). To test whether RTA induced the Bcl-2 phosphorylation, we
analyzed the phosphorylation status of Bcl-2 by immunoblotting with a specific antibody
which recognizes phosphorylation at Ser70. We found a slight increase in the
phosphorylation of Bcl-2 in the RTA transfected-293T cells but the expression levels of
Bcl-2 remained the same either in the absence or presence of RTA (Fig. 6A). In addition,
phosphorylation of Bcl-2 was also found to be elevated upon RTA expression in KSHVinfected TRExBCBL1-RTA cells (Fig. 6B). These results indicate that RTA is able to
induce the Bcl-2 phosphorylation.
JNK signaling is involved in RTA-induced phosphorylation of Bcl-2 and autophagy
activation
It has been shown that Bcl-2 phosphorylation induces dissociation of Beclin 1 and
Bcl-2 and is regulated by the c-JUN N-terminal kinase 1(JNK 1) (54), and the
phosphorylation of JNK-1 is needed to activate its kinase activity prior to
phosphorylation of Bcl-2. Interestingly, an increase in posphorylation of JNK 1 (p-JNK1)
was observed after RTA induction in TRExBCBL-RTA cells (Fig. 6B).
To demonstrate whether RTA employs JNK signaling for Bcl-2 phosphorylation
and autophagy activation, a JNK specific inhibitor, SP600125, was used to study its
effect on Bcl-2 phosphorylation and LC3 conversion with and without RTA expression.
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As shown in Figure 7, Bcl-2 phosphorylation elevated by RTA can be suppressed by the
JNK inhibitor in the 293T (Fig. 7A) and TRExBCBL-RTA cells (Fig. 7B). In addition,
the increase in LC3-II was observed in the presence of RTA, but addition of the JNK
inhibitor reduced RTA-induced LC3-II expression, suggesting that RTA-mediated
autophagy was suppressed by interfering with JNK signaling. We therefore concluded
that RTA stimulates autophagy through JNK-dependent phosphorylation of Bcl-2.

Discussion
Autophagy has been implicated as an antiviral defense mechanism of infected
cells. Autophagy can directly engulf virion particles and/or viral components for
lysosomal degradation, or facilitate viral antigens presentation process via MHC (major
histocompatibility complex) presentation. However, some viruses can evade or
counteract the execution of autophagy, and some viruses can utilize the autophagy
machinery to facilitate their replication and enhance their pathogenic potential (24). Our
previous study found that the autophagy pathway is enhanced by RTA and is involved in
KSHV lytic replication upon stimulation by RTA (56). This current study extended the
observation to show that the induction of autophagy alone is not sufficient to initiate
KSHV lytic replication but can potentiate lytic replication in the presence of RTA. A
proposed model on how RTA utilizes autophagy for virus lytic replication is shown in
Fig. 8. RTA induces Bcl-2 phosphoylation through the JNK signaling pathway to cause
the dissociation of Beclin 1 and Bcl-2. Beclin 1 which is released from Bcl-2 can bind to
class III PI3K complex to initiate the autophagic process. The induction of autophagy
enhances RTA-mediated transactivation of the virus lytic promoters and thereby
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facilitates virus lytic replication. The involvement of autophagy in KSHV replication
supports findings from other herpesviruses, which also involve autophagy during their
infection. Another member of the gammaherpersvirus family, Epstein-Barr virus (EBV),
induces autophagy and the latent membrane protein 1 (LMP1) plays a role in this process.
Induction of autophagy is needed to limit accumulation of the LMP1 protein as well as
modulate B cell transformation (26). The infection by varicella zoster virus (VZV), an
alphaherpesvirus, can also induce autophagy but whether autophagy activation is related
to viral DNA replication or viral pathogenesis remained unknown (46). Our findings in
this study present the first example for a herpesvirus that activates autophagy to facilitate
its viral replication.
Previous studies in our laboratory demonstrated that the viral transactivator RTA
promotes ubiquitin modification of its transcriptional repressors to enable the cellular
proteasome degradation pathway to target and degrade the ubiquitinated-transcriptional
repressors. Consequently, RTA can stimulate lytic gene expression and virus lytic
replication (63). In the current study, we found that inhibition of autophagy reduced the
response of RTA to the target promoters of viral lytic genes, suggesting autophagy
cooperates with RTA to promote reactivation from latency. Since autophagy is a
lysosomal degradation pathway which also targets ubiquitinated proteins for degradation
(7), we suggest that autophagy can also degrade transcriptional repressors to facilitate
RTA-responsive gene expression. This possibility need to be further explored.
We have demonstrated that RTA increases Bcl-2 phosphorylation to release
Beclin 1 from Bcl-2 to activate the autophagy pathway; however, we cannot rule out the
possibility that the competitive binding between Beclin 1 and Bcl-2 can also be mediated
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by other proteins. It has been shown that the BH3-only proteins (Bad or Bim), the
pharmacologic BH3 mimetic ABT737, and the BNIP3L protein induced by hypoxia can
disrupt the interaction between Beclin 1 and Bcl-2 (or Bcl-XL) competitively and thereby
induce autophagy (31, 35, 48). We were attempting to address whether the expression of
pro-apoptotic protein Bad is up-regulated by RTA for autophagy induction since RTA
has been suggested as an apoptotic inducer in uninfected cells (34). However, we did not
observe a significant increase in Bad expression when RTA is expressed (data not shown).
Hence, additional studies are needed to further investigate whether RTA up-regulates the
expression of Bim, BNIP3L, or other BH3-only protein in order to release Beclin 1 from
Bcl-2 for the initiation of autophagy.
Based on our findings, we purpose that RTA induces autophagy through
dissociation of Beclin 1 and Bcl-2 via Bcl-2 phophorylation, which then facilitates virus
reactivation from latency, and this process involves the JNK1 kinase pathway. The JNK
signaling pathway is one of the mitogen-activated protein kinase (MAPK) pathways in
response to stress stimuli, and is required for KSHV primary infection and reactivation of
KSHV from latency (11, 36, 59). Xie et al. showed that MAPK pathways are involved in
the early stages of TPA (12-O-tetradecanoyl-phorbol-13-acetate)-induced KSHV
reactivation from latency and suggested that AP-1 (activator protein 1), a downstream
target of MAPK pathways, is a key transcriptional factor mediating lytic gene expression
(59). In this study, we observed that autophagy is a downstream target of the JNK
signaling pathway and further substantiates the importance of the JNK signaling pathway
during KSHV reactivation from latency. Taken together, the JNK signaling pathway has
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wide-ranging effects that are important for KSHV reactivation, including mediating
autophagy.
During lytic replication, however, the induction of autophagy by RTA may also
be inhibited by KSHV Bcl-2 homolog (vBcl-2), which is inferred as a viral lytic gene
product due to the observation of its mRNA expression at late stages of productive
infection (42). The vBcl-2 protein was shown to have anti-autophagic activity through its
direct interaction with Beclin 1 because the binding affinity of vBcl-2 to Beclin 1 was
higher than that of the cellular Bcl-2 (29, 39). Moreover, vBcl-2 does not have the
phosphorylation sites of Bcl-2 (38). Thus, RTA may not interrupt the interaction between
vBcl-2 and Beclin 1 to initiate autophagy through JNK1 kinase pathway when vBcl-2 is
expressed. It is likely that autophagy may be transiently activated by RTA only at the
very early stage of viral lytic infection but then counteracted by the expression of vBcl-2
at the late stage of viral lytic infection, reflecting an intricate mechanism that the virus
regulates viral gene expression at different phases of infection. Interestingly, it has been
shown the vBcl-2 protein was only detected in the spindle cells from late-stage KS
lesions, but not in stimulated PEL cell lines even though its mRNA is transcribed during
the lytic phase in the PEL cell line (42, 58). Therefore, whether vBcl-2 is able to inhibit
RTA-stimulated autophagy as suggested during viral lytic phase remained to be
determined.
It is also possible that RTA may use an alternative mechanism for inducing
autophagy in addition to interfering with the interaction between Beclin 1 and Bcl-2.
RTA may directly up-regulate the expression of genes which are involved in the
autophagic machinery since RTA is a transcriptional activator. In fact, a number of
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studies have shown that an increase in the expression level of the Atg proteins, such as
Beclin 1, LC3, and Atg5, can activate the autophagic process (40, 44, 47, 66). We have in
fact detected the expression of mRNA of autophagy-related genes, including Beclin 1,
Atg5, Atg7, and LC3 during KSHV lytic reactivation, but no obvious changes in those
mRNA levels were detected when RTA was expressed (data not shown), suggesting that
RTA does not induce autophagy by directly activating the expression of these autophagyrelated genes. It nevertheless remains possible that there may be other autophagy-related
genes activated by RTA.
In conclusion, we provide evidence that RTA stimulates autophagy through JNKdependent Bcl-2 phosphorylation. Furthermore, KSHV utilizes the autophagy pathway to
mediate the transactivation function of RTA and enhance KSHV lytic replication. Overall,
those findings further reveal that KSHV can hijack multiple cellular machineries,
including autophagy, for its viral DNA replication.
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Figures and figure legends
Fig. 1
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Fig. 1. Autophagy is not sufficient to trigger KSHV lytic reactivation.
(A) Rapamycin treatment induces LC3 conversion. TRExBCBL-RTA cells were treated
with Rapamycin or DMSO for 48 hours. LC3 was analyzed by Western blot. (B) ORF57,
(C) K8, and (D) K8.1 mRNA levels from TRExBCBL-RTA treated with DMSO or
Rapamycin and/or Doxycycling (Dox) were quantified by real-time PCR. The results
shown are based on the average from three separate experiments. Results are expressed as
mean +/- S.D. Asterisks indicate p <0.05 (student’s t test).
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Fig. 2
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Fig. 2. Defective autophagy affects RTA-mediated transactivation of gene promoters.
(A) ORF57, (B)PAN, and (C)LTR promoter reporters were co-transfected with (A,B)
RTA or (C) HIV Tat expression plasmid into various knockdown 293T cells expressing
Beclin 1 (BECN), Atg5, or scramble (N) shRNA. Luciferase activity was measured at 24
hr post-transfection. All results shown are based on the average from three independent
repeats. Results are shown as mean +/- S.D. (D) The RTA expression levels in wild type
and various knockdown 293T cells were analyzed by Western blot with anti-Flag
antibody.
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Fig. 3
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Fig. 3. The transactivation domain of RTA is required for RTA-induced autophagy.
(A) Schematic representation of full-length and truncated RTA constructs. The numbers
indicate amino-acid positions. NLS and AD indicate nuclear localization signal and
activation domain, respectively. Various RTA expression constructs and pCMVtag2A
(vector) were expressed in the 293T cells and their expression levels were analyzed by
Western blot with anti-Flag antibody. (B) Quantitation of the number of cells containing
GFP-LC3 punctate dots in transfected 293T cells. GFP-LC3 was co-transfected with
vector or various RTA deletion constructs into 293T cells for 22 hours and the cells with
GFP dots were visualized using a fluorescent microscope. (C, D) The responsiveness of
(C) ORF57 and (D) PAN promoters to wild-type and various RTA deletion mutants. The
promoter reporter was co-transfected with various RTA expression plasmids into 293T
cells. Luciferase activity was measured at 24 hr post-transfection. All results shown are
based on the average from three independent repeats. Results are expressed as mean +/S.D.
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Fig. 4
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Fig. 4. RTA does not affect mTOR kinase activity.
293T cells were treated with rapamycin or DMSO, or transfected with pCMVtag2A (V),
RTA, or Beclin 1 (BECN1) expression plasmid. The expression levels of mTOR, pmTOR, p70S6K, P-70S6K, and tubulin were analyzed by Western blot with specific
antibodies.
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Fig. 5
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Fig. 5. RTA interrupts the interaction of Beclin 1 and Bcl-2.
pCMVtag2A (V) or RTA expression plasmid was transfected into 293T cells. The
immunoprecipitation (IP) was carried out by anti-Bcl-2 antibody-conjugated agarose. The
expression levels of Beclin 1, Bcl-2, RTA and GAPDH were analyzed by Western blot
(WB) with specific antibodies.
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Fig. 6
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Fig. 6. RTA stimulates phosphorylation of Bcl-2.
(A) pCMVtag2A (V) and RTA expression plasmid was transfected into 293T cells. The
expression levels of protein as indicated were analyzed by Western blot. (B) To induce
RTA expression, TRExBCBL-RTA cells were treated with doxycyline (Dox) for the
indicated time. Western blot analysis was performed using the specific antibodies as
indicated. The numbers indicate the relative amount of the p-Bcl-2 and p-JNK1 proteins
that were normalized with the GAPDH protein.
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Fig. 7
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Fig. 7. Inhibition of JNK activity reduces RTA-stimulated Bcl-2 phosphorylation
and LC3 conversion.
(A) Vector (V) or RTA expression plasmid was transfected into 293T cells. (B)
TRExBCBL-RTA cells were treated with doxycyline (Dox) to induce RTA expression.
The transfected 293T cells and the induced TRExBCBL-RTA cells were treated with
SP600125 for 3 hr, and Western blot analysis was performed using the specific antibodies
as indicated. The numbers indicate the relative amount of the p-JNK1, p-Bcl-2 and, LC3II proteins that were normalized with the GAPDH protein.
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Fig. 8
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Fig. 8. Proposed model of autophagy stimulated by RTA for KSHV lytic replication.
RTA induces the dissociation of Beclin 1 and Bcl-2 through JNK-dependent Bcl-2
phosphorylation to stimulate autophagic process. Based on our present and previous
results (51), RTA-activated autophagy is essential for RTA-mediated transactivation of
lytic gene promoters and lytic replication.

181

CHPATER 5
CONCLUDING REMARKS

KSHV RTA is a key regulator for initiation of KSHV lytic replication. This
research attempts to demonstrate the molecular mechanism utilized by RTA to upregulate lytic gene expression and facilitate virus lytic activation. From our studies, the
following conclusions can be made.

GC-rich DNA sequence in the RTA responsive element (RRE) and multiple RREs
are required for RTA-mediated transactivation of its target gene promoters, such as
the ORF57 promoter
The sequence of the KSHV RTA responsive element (RRE) was initially
identified to be AT rich or A/T trinucleotide (1, 3, 4). We identified a new RRE
consisting of GC-rich sequence (ACCN9GG) based on homology to the consensus
sequence of the EBV RRE. This sequence can be found in a number of RTA-responsive
lytic gene promoters, including ORF57, PAN, K12, K2, and MIP. Importantly, the
variation of N9 sequence in each promoter element may contribute to differences in the
binding affinity and transactivation responsiveness to RTA. We focused on one of the
lytic gene promoter ORF57, which is highly responsive to RTA. Previous studies in our
laboratory have identified two RREs (RRE1 and RRE2) in the ORF57 promoter, and both
contain two dissimilar AT-rich sequences (1, 8). In the current study, a newly identified
RRE with high GC content was named RRE3. The three RREs are located in very close
proximity to each other in the ORF57 promoter. All of them can be bound by the RTA
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protein independently, but their binding affinities to RTA are distinct. For RTAmediated transactivation of the ORF57 promoter, RRE2 is essential, but not sufficient.
Two of the RREs (RRE1/RRE2 or RRE3/RRE2) and the RBP-Jκ binding site are
required to obtain optimal transcriptional activation in response to RTA. These results
suggest that the ability of RTA to mediate transactivation is distinct from its ability to
binding to its responsive elements. This study also suggests a novel mechanism that
multiple RREs are utilized by RTA for lytic gene expression.

A cellular pathway, autophagy, employed by RTA for virus reactivation
The results of this study showed that autophagy is enhanced during KSHV lytic
replication that is induced by either chemical stimuli or RTA, and suppression of the
autophagy pathway reduced RTA-mediated lytic gene expression and viral DNA
replication. It indicates that autophagy, in conjunction with RTA, positively regulates the
KSHV lytic cycle. However, autophagy alone is not sufficient to activate viral replication.
Inhibition of autophagy prominently reduced the efficiency of early phases of viral
reactivation. Our current studies also demonstrated that RTA activated the autophagy
pathway independent of other viral proteins. Taken together, autophagy is activated and
utilized by RTA to reactivate viral lytic replication. To date, HBV (hepatitis B virus)
which is another DNA virus, in addition to KSHV, was reported to induce autophagy for
its DNA replication (7). However, it is not clear how autophagy regulates HBV DNA
replication. A number of RNA viruses such as poliovirus, coxsackievirus, hepatitis C
virus, and dengue virus have been implicated to induce autophagy and appear to utilize
the membrane of autophagic vacuoles as a site for their viral genome replication (6).
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Since KSHV DNA replication occurs in the nucleus, it is unlikely that KSHV could take
advantage of autophagic vacuoles as a site of its DNA replication. In fact, our results
showed that defective autophagy causes less transactivation of lytic gene promoters in
response to RTA, indicating that autophagy is employed by RTA to optimize
transcriptional activation of the target promoters and then facilitate lytic reactivation.
Autophagy could be a factor but may not the major cellular machinery used by RTA to
regulate its transactivation function and lytic replication. Previous studies in our
laboratory have demonstrated that another cellular degradation pathway, the ubiquitinproteasome pathway, regulates RTA-mediated transactivation and lytic replication by
degrading the ubiquitinated repressors and then enables RTA to activate its target gene
promoters (11). Since autophagy is a lysosomal degradation pathway, it is highly likely
that autophagy is involved in the degradation of cellular transcriptional repressors.
The overall conclusions of this dissertation can be summarized as Fig. 1. RTA
induces Bcl-2 phosphorylation through JNK1 activity to interfere with the interaction of
Beclin 1 and Bcl-2. Beclin 1 released from Bcl-2 can then interact with the class III PI3K
complex and initiates the autophagy pathway. Autophagy supports RTA to stimulate lytic
gene expression, and autophagy-modulated RTA transactivation may involve the
autophagy degradation process. It has been demonstrated that RTA possesses E3-like
ubiquitin ligase activity which ubiquitinates cellular transcriptional repressors for
proteasome degradation (2, 11, 12). Alternatively, autophagy may target ubiquitinated or
un-ubiquitinated transcriptional repressors for lysosomal degradation. Once repressors
are released from KSHV promoters and degradated by the cellular degradation systems,
RTA or RTA-coactivator complexes can bind to RRE in the promoter (for example, RTA
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and RBP-Jκ binds to multiple RREs and RBP-Jκ binding sites in the ORF57 promoter) to
induce gene expression and then facilitate virus lytic replication. Moreover, RTA-induced
autophagy may facilitate virus lytic replication through an unknown mechanism in
addition to assisting RTA transactivation function. This possibility needs to be further
investigated.

Future direction
To substantiate whether RTA-induced autophagy is responsible for degradation of
the transcriptional repressors
It has been reported that a number of viruses can activate autophagy for their
genome replication; however, some of those viruses, such as Hepatitis C virus and
coxsackievirus B 3, induce autophagosome formation only but not autolysosome
maturation, suggesting that the degradation function of autophagy is blocked (5, 9). In
our current studies, we observed that RTA is able to promote the formation of
autophagosomes and autolysosomes, and degradation of LC3-II bound to the inner
membrane of autophagosome can be inhibited by bafilomycin A1, an inhibitor of
autolysosome maturation. Therefore, RTA-induced autophagy may include the
degradation process, and RTA may utilize this feature of autophagy to overcome the
transcriptional inhibition derived from the transcriptional repressors. For example,
previous studies in our laboratory showed that NF-κB p65 was degraded in the presence
of RTA, and this degradation was not suppressed when the 26S proteasome degradation
pathway was inhibited (11). It suggests that another potential degradation mechanism,
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such as autophagy, is involved in RTA-induced degradation of NF-κB p65. More
experiments will be needed to address these questions.
To further investigate the alternative mechanism of RTA-stimulated autophagy.
In current studies, we have demonstrated that RTA stimulates the autophagy
pathway through JNK1-dependent Bcl-2 phosphorylation. However, how RTA is able to
trigger the JNK signaling pathway which occurs in the cytoplasm will require further
investigations. In addition to Bcl-2 phosphorylation by JNK1, it is also possible that RTA
could induce the expression of proteins, such as BH3-only protein, Bim, and BNIP3L, to
interrupt the interaction between Beclin 1 and Bcl-2 for autophagy initiation, or RTA
could directly up-regulates autophagy-related protein to trigger the autophagy pathway
since RTA is a transcriptional activator. These possibilities will also need to be further
studied in future.
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Figure and figure legend
Fig. 1
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Fig. 1. Proposed mechanism utilized by RTA for KSHV lytic replication.
RTA exerts its E3-like ubiquitin ligase activity to promote the ubiquitination (Ub) of it
repressors and allows the ubiquitinated repressors to undergo the 26S proteasome
degradation pathway. Consequently, RTA is able to activate transactivation of lytic gene
promoters and facilitates KSHV lytic replication (10, 11). Current study demonstrated
that RTA induces the dissociation of Beclin 1 and Bcl-2 through JNK-dependent Bcl-2
phosphorylation and then stimulates the autophagic process. Additionally, autophagy
positively regulates RTA-mediated transactivation of target gene promoters and
facilitates KSHV lytic replication. The question marks indicate the potential mechanisms
(repressor degradation) by which autophagy modulate RTA transactivation function and
the unknown mechanism by which autophagy regulates KSHV lytic replication.

